Document:

Exhibit 10.3

 

Execution Version

 

 

 

AMENDED AND RESTATED LIMITED LIABILITY
COMPANY AGREEMENT OF

 

IBIO CMO LLC

 

A Delaware Limited Liability Company

 

Dated as of January 13,
2016

 

 

 

THE UNITS EVIDENCED BY
THIS AMENDED AND RESTATED LIMITED LIABILITY COMPANY AGREEMENT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED,
OR UNDER THE SECURITIES LAWS OF ANY STATE OR FOREIGN JURISDICTION. SUCH INTERESTS MAY NOT BE SOLD, ASSIGNED, PLEDGED OR OTHERWISE
DISPOSED OF AT ANY TIME WITHOUT EFFECTIVE REGISTRATION UNDER SUCH ACT AND LAWS OR EXEMPTION THEREFROM AND COMPLIANCE WITH THE OTHER
SUBSTANTIAL RESTRICTIONS ON TRANSFERABILITY SET FORTH HEREIN.

 

THE UNITS REPRESENTED
BY THIS AMENDED AND RESTATED LIMITED LIABILITY COMPANY AGREEMENT ARE ALSO SUBJECT TO ADDITIONAL RESTRICTIONS ON TRANSFER SET FORTH
IN THIS AMENDED AND RESTATED LIMITED LIABILITY COMPANY AGREEMENT.

  

     

     

    

  

TABLE OF CONTENTS

 

	 	 	Page
	 	 	 
	Article 1 ORGANIZATIONAL MATTERS; PURPOSE; TERM	1
	1.1	Formation of Company	1
	1.2	Name	1
	1.3	Principal Office	1
	1.4	Foreign Qualification	1
	1.5	Purpose and Scope	1
	1.6	Term	1
	1.7	No State Law Partnership	1
	1.8	Units are Securities	2
	1.9	Certification of Units	2
	Article 2 MEMBERSHIP; DISPOSITIONS OF INTERESTS	3
	2.1	Members	3
	2.2	Dispositions of Units	3
	2.3	No Release	3
	2.4	Creation of Additional Units	3
	2.5	Resignation	4
	2.6	Liability to Third Parties	4
	2.7	Representations by Members	4
	Article 3 MANAGEMENT OF THE COMPANY	4
	3.1	Management	4
	3.2	Reimbursement of Expenses	6
	3.3	Compensation	7
	3.4	No Liability of the Members	7
	3.5	Indemnification of the Members and Others; Insurance	7
	3.6	No Fiduciary Duties; Conflicts of Interest	8
	3.7	Indemnification and Reimbursement for Payments on Behalf of a Member	9
	3.8	Officers	9
	Article 4 ACCOUNTING AND REPORTING	9
	4.1	Maintenance of Books	9
	4.2	Reports; Access to Books and Records	9
	4.3	Bank Accounts	11
	Article 5 CAPITAL CONTRIBUTIONS	11
	5.1	Capital Contributions	11
	5.2	Return of Contributions	11
	5.3	Member Loans	11
	5.4	Capital Accounts	12
	Article 6 DISTRIBUTIONS	12
	6.1	Distributions	12
	6.2	Successors	12
	6.3	Right of Set-Off	12

 

     ii

     

    

 

 

	Article 7 ALLOCATIONS AND TAX MATTERS	12
	7.1	Allocations of Profits or Losses	12
	7.2	Regulatory Allocations	13
	7.3	Tax Allocations	14
	7.4	Curative Allocations	15
	7.5	Other Allocation Rules	15
	7.6	Tax Returns	16
	7.7	Tax Elections	16
	7.8	Tax Matters Member	16
	Article 8 WITHDRAWAL, DISSOLUTION, LIQUIDATION AND TERMINATION 	17
	8.1	Dissolution, Liquidation, and Termination Generally	17
	8.2	Liquidation and Termination	17
	8.3	Deficit Capital Accounts	17
	8.4	Cancellation of Certificate	17
	8.5	Reasonable Time for Winding Up	18
	8.6	Return of Capital	18
	8.7	Antitrust Laws	18
	8.8	Other Remedies	18
	Article 9 MISCELLANEOUS PROVISIONS	18
	9.1	Confidentiality	18
	9.2	Notices	19
	9.3	Entireties; Amendments	19
	9.4	Waiver	19
	9.5	Severability	20
	9.6	Ownership of Property and Right of Partition	20
	9.7	Involvement of Members in Certain Proceedings	20
	9.8	Interest	20
	9.9	Counterparts	20
	9.10	No Third Party Beneficiaries	20
	9.11	Further Assurances	20
	9.12	Public Statements; Press Release	20
	9.13	Delivery by Facsimile or Email	21
	9.14	Governing Law; Dispute Resolution.	21
	9.15	Remedies Cumulative; Specific Performance	22
	9.16	Ratification of Certain Agreements and Transactions	23
	Article 10 DEFINITIONS; CONSTRUCTION	23
	10.1	Definitions.	23
	10.2	Captions, References	28
	10.3	Strict Construction	29

 

EXHIBITS AND SCHEDULES

 

Exhibit A—Schedule of Members

 

     iii

     

    

  

AMENDED AND RESTATED LIMITED LIABILITY
COMPANY AGREEMENT OF IBIO CMO LLC

 

This AMENDED AND RESTATED
LIMITED LIABILITY COMPANY AGREEMENT (this “Agreement”) of iBio CMO LLC, a Delaware limited liability company
formed pursuant to the Certificate (the “Company”), is made and entered into as of January 13, 2016. All capitalized
terms used and not otherwise defined herein shall have the meanings given to them in Section 10.1.

 

ARTICLE 1

ORGANIZATIONAL MATTERS;
PURPOSE; TERM

 

1.1           Formation
of Company. The Company has been organized as a Delaware limited liability company by filing a certificate of formation (the
“Certificate”) under the Act on December 16, 2015. The Certificate is in all respects approved, and the Members
hereby agree to continue the Company.

 

1.2           Name.
The name of the Company shall be “iBio CMO LLC,” and all Company business must be conducted in that name or such other
name as the Board approves.

 

1.3           Principal
Office. The principal office of the Company shall be at 8800 Health Science Center Parkway, Bryan, Texas 77807-1107, or at
such other location as the Board and each of the Members from time to time may approve.

 

1.4           Foreign
Qualification. Before the Company conducts business in any jurisdiction other than the State of Delaware, the Company shall
comply with all requirements necessary to qualify the Company as a foreign limited liability company in such jurisdiction. At the
request of the Board, each Member shall execute, acknowledge, swear to and deliver all certificates and other instruments that
are reasonably necessary or appropriate to qualify, continue or terminate the Company as a foreign limited liability company in
all jurisdictions in which the Company may conduct business.

 

1.5           Purpose
and Scope. The Company has been organized to (a) lease and operate a pharmaceutical manufacturing facility in Bryan, Texas,
(b) perform all other activities reasonably necessary or incidental to the furtherance of the aforementioned purposes, and (c)
conduct any other lawful business, purpose or activity, as determined by the Board and approved by each of the Members, which may
be conducted by a limited liability company under the Act.

 

1.6           Term.
The Company shall commence on the effective date of the Certificate and shall have perpetual existence, unless sooner dissolved
as herein provided.

 

1.7           No
State Law Partnership.   The Company shall not be a partnership or joint
venture under any state or federal law, and no Member shall be a partner or joint venturer of any other Member for any purposes,
other than under the Code and other applicable tax laws, and this Agreement may not be construed otherwise.

 

     

     

    

  

1.8           Units
are Securities. Each Unit shall constitute a “security” within the meaning of and shall be governed by (a)
Article 8 of the Uniform Commercial Code (including Section 8-102(a)(15) thereof) as in effect from time to time in the State
of Delaware, and (b) the Uniform Commercial Code of any other applicable jurisdiction that now or hereafter substantially
includes the 1994 revisions to Article 8 thereof as adopted by the American Law Institute and the National Conference of
Commissioners on Uniform State Laws and approved by the American Bar Association on February 14, 1995.

 

1.9           Certification
of Units. Units shall be issued in non-certificated form; provided that the Board may cause the Company to issue certificates
to a Member representing the Units held by such Member. If any Unit certificate is issued, then such certificate shall bear a legend
substantially in the following form:

 

This certificate
evidences a membership interest representing an interest in iBio CMO LLC and shall constitute a “security” within
the meaning of and shall be governed by (i) Article 8 of the Uniform Commercial Code (including Section 8-102(a)(15) thereof)
as in effect from time to time in the State of Delaware, and (ii) the Uniform Commercial Code of any other applicable jurisdiction
that now or hereafter substantially includes the 1994 revisions to Article 8 thereof as adopted by the American Law Institute
and the National Conference of Commissioners on Uniform State Laws and approved by the American Bar Association on February 14,
1995.

 

The membership interest
in iBio CMO LLC represented by this certificate is subject to restrictions on transfer set forth in that certain Amended and Restated
Limited Liability Company Agreement of iBio CMO LLC, dated as of January 13, 2016, by and among the members from time to time party
thereto, as the same may be amended from time to time.

 

The membership interest
in iBio CMO LLC represented by this certificate has not been registered under the United States Securities Act of 1933, as amended,
or under any other applicable securities laws. Such membership interest may not be sold, assigned, pledged or otherwise disposed
of at any time without effective registration under such Act and laws or, in each case, exemption therefrom.

 

    2 

     

    

  

ARTICLE 2

MEMBERSHIP; DISPOSITIONS
OF INTERESTS

 

2.1           Members.
Each Member’s interest in the Company, including such Member’s interest, if any, in the capital, income,
gains, losses, deductions and expenses of the Company and the right to receive distributions of funds and to vote on certain
Company matters as provided in this Agreement shall be represented by units of limited liability company interest (each, a
“Unit”). No Person may be a Member without the ownership of a Unit. The Members shall have only such
rights and powers as are granted to them pursuant to the express terms of this Agreement and the Act. Except as otherwise
expressly provided in this Agreement, no Member, in such capacity, shall have any authority to bind, to act for, to sign for
or to assume any obligation or responsibility on behalf of, any other Member or the Company. Each Unit that was issued and
outstanding immediately prior to the execution and delivery of this Agreement and owned by iBio is hereby automatically,
without any action required on the part of the Company or any Member, converted into a number of Units such that the
aggregate number of Units issued and outstanding immediately following the execution and delivery of this Agreement and held
by iBio is as set forth on Exhibit A.

 

2.2           Dispositions
of Units. A Member may not make an assignment, transfer, sale or other disposition (voluntarily, involuntarily or by
operation of law, or any derivative transaction, including any short sale, collar, hedging or other derivative transaction
that has the effect of materially changing the economic benefits and risks of ownership) (each, a
“Transfer”) of all or any portion of its Units, nor pledge, mortgage, hypothecate, grant a security
interest in, or otherwise encumber (each, an “Encumbrance”) all or any portion of its Units, except with
the prior written consent of each other Member, which shall not be unreasonably withheld, conditioned, or delayed; provided that
Bryan Capital Investors LLC (“Bryan”) may transfer all or part of its Units to an Affiliate without such
consent. Any attempted Transfer or Encumbrance of a Unit, other than in strict accordance with this Section 2.2, shall
be void.         A Change in Control of iBio, Inc. (“iBio”),
whether by a sale of all or substantially all of its assets, merger or otherwise, shall not be deemed a Transfer requiring
consent hereunder. A Change in Control of Bryan, however, whether by a sale of all or substantially all of its assets, merger
or otherwise, shall be deemed a Transfer requiring consent hereunder (except to the extent that the deemed Transfer is to a
Person or Persons to whom, if Units were directly Transferred, consent would not be required under this Section 2.2),
which consent shall not be unreasonably withheld, conditioned or delayed. A Person to whom a Unit is Transferred or
a permitted successor of a Member’s interest through a Change in Control, in each case in accordance with the terms and
conditions of this Agreement, shall be admitted to the Company as a Member.

 

In connection with
any Transfer of a Unit, and any admission of an assignee as a Member, the Member making such Transfer and the assignee shall furnish
the Board with such documents regarding the Transfer as they may reasonably request (in form and substance satisfactory to the
Board), including a copy of the Transfer instrument and a ratification by the assignee of this Agreement.

 

2.3           No
Release.  No Transfer of a Unit shall effect a release of the transferring Member from any liabilities to the Company
or the other Members arising from events occurring prior to the Transfer.

 

2.4           Creation
of Additional Units. Subject to Section 2.2, additional or new Units may be created and issued to existing
Members or to other Persons, and such Persons may be admitted to the Company as Members, only with the approval of the Board
and each of the Members, on such terms and conditions as the Board may determine and each of the Members may approve. The
Company shall thereafter reflect the issuance of any additional Units and the admission of any new Member or the creation of
any new class or group of Members or Units in an amendment to this Agreement which shall be valid and binding on all
Members.

 

    3 

     

    

  

2.5           Resignation.
Except as required by law, a Member may not resign or withdraw from the Company without the consent of the Board and each
of the other Members.

 

2.6           Liability
to Third Parties. No Member shall be liable for the debts, obligations or liabilities of the Company.

 

2.7           Representations
by Members. Each Member represents and warrants to the other Members and to the Company that:

 

(a)          all
transactions contemplated by this Agreement to be performed by such Member have been duly authorized by all necessary action and
do not require the consent or approval of any third party; and

 

(b)         such
Member has all necessary power with respect thereto.

 

ARTICLE 3

MANAGEMENT OF THE COMPANY

 

3.1           Management.

 

(a)     Board
of Managers.

 

(i)            Management
by the Board. The management of the affairs, property and business of the Company shall be vested in a Board of Managers
(the “Board”) consisting of three (3) managers (each a “Manager”). The Board shall
manage the affairs of the Company and make all decisions with regard thereto, except (i) where the approval of a Member is
expressly required by a non-waivable provision of applicable law or (ii) as otherwise provided under Section 3.1(b) or
as expressly provided in any other provision of this Agreement. The vote of a majority of the Managers shall be the act of
the Board. Each Manager shall have one vote. The Managers shall perform their duties in good faith and in the best interest
of the Company, exercising the care a prudent person would use under similar circumstances.

 

(ii)           Appointment
of Managers.

 

(A) Each Member, so
long as such Member holds more than twenty five percent (25%) of the outstanding Units, shall be entitled to appoint one Manager.

 

(B) The Members holding
a majority of the outstanding Units shall be entitled to appoint the remaining Managers.

 

(iii)          Removal
and Replacement of Managers. A Manager appointed pursuant to paragraph (A) of Section 3.1(a)(ii) may be removed or
replaced at any time, with or without cause, only by the Member that has appointed such Manager. A Manager appointed pursuant
to paragraph (B) of Section 3.1(a)(ii) may be removed or replaced at any time, with or without cause, by the Members
holding a majority of the outstanding Units.

 

    4 

     

    

  

(iv)        Meetings
of the Board. Regular meetings of the Board shall be held quarterly at the principal offices of the Company or such other
place as determined by the Board. Special meetings of the Board may be called by any Manager, upon not less than 24
hours’ notice to each other Manager either personally or by telephone, facsimile, electronic mail or other electronic
means, setting forth the time and place of such meeting. Managers may participate in any such meeting by telephone or any
other form of remote communication by means of which all persons participating in the meeting can communicate with each
other. A quorum for the transaction of business at a meeting of the Board shall exist when (x) at least two Managers,
including at least one Manager designated by each Member that is entitled to appoint a Manager pursuant to Section
3.1(a)(ii)(A) and has appointed such Manager, and (y) if applicable, each representative designated by a Member pursuant
to Section 3.1(a)(v) if such Member has not appointed a Manager pursuant to Section 3.1(a)(ii)(A), are
participating in the meeting in a manner permitted by the immediately preceding sentence. Any action required or permitted to
be taken at any meeting of the Board may be taken without a meeting, if a written consent thereto is signed by each
Manager.

 

(v)         Observer
Rights.  At any time and for so long as a Member is entitled to appoint
a Manager but has not done so (or has removed and not replaced such Manager), one representative of such Member shall have the
right to attend all meetings of the Board in a nonvoting observer capacity, to receive notice of such meetings, and to receive
all information provided by the Company to the Board.

 

(b) Major
Decisions. Without limiting the generality of Section 3.1(a), and in addition to any other provision in this
Agreement expressly requiring such consent, the Board and the Company shall not take any of the actions set forth in
paragraphs (i) through (xvi) below (and shall not permit any of subsidiaries of the Company to take any such actions) without
the consent of each of the Members. Such consent may be in the form of a written consent signed by all of the Members or
approval of the action at a meeting of the Members held in accordance with Section 3.1(c).

 

(i)          Authorize,
issue or sell any Units or other equity securities or admit new Members to the Company or any subsidiary of the Company or redeem
or purchase any Units or permit the withdrawal (except as required by law) of any Member from the Company;

 

(ii)         Permit
any Member to Transfer any Units or permit any Encumbrance of any Member’s Units (other than as specifically permitted pursuant
to Section 2.2);

 

(iii)        Change
the scope or purpose of the Company’s business or the location of the Company’s principal office;

 

(iv)        Form
any subsidiary;

 

(v)         Incur
or create any indebtedness, amend, waive or modify the terms of any indebtedness, or guarantee any indebtedness, other than in
the ordinary course of business;

 

    5 

     

    

  

(vi)        Make
any loans or advance any payments to third parties, other than in the ordinary course of business (“ordinary course”
being understood for these purposes to include payments constituting trade deposits made in satisfaction of accounts payable);

 

(vii)       Make
any distribution or dividend;

 

(viii)      Liquidate,
dissolve, wind up the Company, or commence any voluntary proceeding seeking reorganization or other similar relief or appoint any
liquidator upon dissolution of the Company;

 

(ix)         Enter
into, revise or amend any contract, agreement or transaction with (including any loans or payments to) any Member or any Affiliate
of a Member;

 

(x)          Pay
or agree to provide any compensation to any Manager;

 

(xi)         Elect
to change the income tax classification of the Company;

 

(xii)        Amend,
modify or supplement this Agreement or the Certificate, or alter any of the rights, preferences or privileges corresponding to
any Units;

 

(xiii)       Create
or permit any lien over any of the assets of the Company (other than liens arising in the ordinary course of business);

 

(xiv)      Terminate
that certain License Agreement, dated as of the date hereof, by and between the Company and iBio;

 

(xv)       Enter
into, amend, supplement, modify, waive or terminate any derivative transaction; or

 

(xvi)      Agree,
commit or represent to do any of the foregoing.

 

(c)   Meetings
of the Members. Regular meetings of the Members shall be held annually at the principal offices of the Company or such
other place as determined by the Members. Special meetings of the Members, including for purposes of considering any matter
set forth in Section 3.1(b), may be called by any Member, upon not less than 24 hours’ notice to each other
Member either personally or by telephone, facsimile, electronic mail or other electronic means, setting forth the time and
place of such meeting. Representatives of the Members may participate in any such meeting by telephone or any other form of
remote communication by means of which all persons participating in the meeting can communicate with each other. A quorum for
the transaction of business at a meeting of the Members shall exist when at least one representative of each Member is
participating in the meeting in a manner permitted by the immediately preceding sentence. Any action required or permitted to
be taken at any meeting of the Members may be taken without a meeting, if a written consent thereto is signed by each
Member.

 

3.2           Reimbursement
of Expenses. Each Member, Manager, officer of the Company and representative designated by a Member pursuant to Section
3.1(a)(v) shall be reimbursed by the Company for all reasonable out-of-pocket expenses actually incurred by it directly
in conjunction with the business and affairs of the Company when acting on behalf of the Company at the request of the Board.
Each such Member, Manager, officer or representative designated by a Member pursuant to Section 3.1(a)(v), as the case
may be, shall provide reasonable supporting verification to the Company for all expenditures for which any reimbursement is
requested.

 

    6 

     

    

  

3.3           Compensation.
No compensatory payment shall be made by the Company to a Member, except as approved by the Board and each of the
Members.

 

3.4           No
Liability of the Members. To the maximum extent permitted under applicable law, no Member or Manager, or their respective
Affiliates, shall be liable to any Member, Manager or the Company for (a) any action taken or failure to act as a Member or
Manager or on behalf of a Member or Manager with respect to the Company unless such action taken or failure to act
constitutes a breach of this Agreement, gross negligence or willful misconduct, and then only to the extent of such
Member’s, Manager’s or such other Person’s breach, gross negligence or willful misconduct, or (b) any
action or inaction arising from reliance upon the opinion or advice of legal counsel, accountants or any other Person as to
matters that such Member or Manager believes to be within such Person’s professional or expert competence or
information or reports prepared by one or more agents or employees of the Company. Notwithstanding the foregoing, iBio hereby
assumes liability for and agrees to indemnify, defend and hold harmless the Company, Bryan, and their respective officers,
directors, equityholders, partners, employees, agents and Affiliates, from and against all losses, claims, damages,
liabilities, obligations, fines, penalties, judgments, settlements, costs, expenses and disbursements (including
attorneys’ fees and expenses), arising out of the ownership, control or operation of the Company prior to the date
hereof; provided that notice of any claim for indemnification pursuant this sentence shall be delivered to iBio on or
before the 18-month anniversary of the date hereof; and provided further that, if notice of a claim for
indemnification is delivered by such date, iBio’s indemnification obligations with respect to such claim shall survive
until such claim is finally and fully resolved.

 

3.5           Indemnification
of the Members and Others; Insurance.

 

(a)   To
the maximum extent permitted under applicable law, the Company shall indemnify each of the Members, Managers and their respective
employees, officers, directors, members, agents and Affiliates (each, an “Indemnified Party”) against any losses,
liabilities, damages or expenses (including attorney fees and expenses in connection therewith and amounts paid in settlement
thereof) to which an Indemnified Party may directly or indirectly become subject in connection with the Company or in connection
with any involvement with any Person in which the Company has a direct or indirect investment. The Company may, upon the approval
of the Board and each of the Members, pay the expenses incurred by any such Indemnified Party in connection with any proceeding
in advance of the final disposition, so long as the Company receives an undertaking by such Indemnified Party to repay the full
amount advanced if there is a final determination that such Indemnified Party is not entitled to indemnification as provided herein.
An Indemnified Party shall not be required to first seek indemnification from other available sources, if any, prior to obtaining
indemnification hereunder.

 

    7 

     

    

  

(b)  The Company
shall use its reasonable best efforts to obtain within 60 days of the date hereof, and thereafter at all times maintain, directors
and officers liability insurance policies on terms and in amounts deemed satisfactory by the Board with the approval of each of
the Members, and all of the Managers shall be included as insureds under such policies. The Company’s directors and officers
liability insurance policies shall not be cancellable by the Company without the prior written approval of the Board and of each
of the Members, and shall include non-rescindable “Side A” coverage.

 

3.6           No
Fiduciary Duties; Conflicts of Interest.

 

(a)          The
only duties owed by any Member or Manager to the Company and the other Members and Managers are set forth in this Agreement. The
Members and Managers shall not, to the maximum extent permitted by the Act and other applicable law, owe any other duties (including
fiduciary duties) as a Member or Manager to the other Members, Managers or the Company, notwithstanding anything to the contrary
existing at law, in equity or otherwise. The provisions of this Agreement, to the extent that they restrict or eliminate the duties
(including fiduciary duties) and liabilities of a Member or Manager otherwise existing at law or in equity, are agreed by the Members
to replace such duties and liabilities of such Members and Managers.

 

(b)          Except
as otherwise expressly provided in this Agreement or any other contractual arrangements between the Company and one or more Members
or Managers, any Member or Manager may engage in or possess any interest in another business or venture of any nature and description,
independently or with others, whether or not such business or venture is competitive with the Company or any of its subsidiaries,
and neither the Company nor any other Member or Manager shall have any rights in or to any such independent business or venture
or the income or profits derived therefrom, and the doctrine of corporate opportunity or any analogous doctrine shall not apply
to the Members, Managers or the Affiliates thereof. The pursuit of any such business or venture shall not be deemed wrongful,
improper or a breach of any duty hereunder, at law, in equity or otherwise. Any Member, Manager or Affiliate thereof shall be
able to transact business or enter into agreements with the Company to the fullest extent permissible under the Act, subject to
the terms and conditions of this Agreement.

 

(c)          Except
as otherwise expressly provided in this Agreement or any other contractual arrangements between the Company and one or more Members
or Managers, if a Member or Manager acquires knowledge, other than solely from or through the Company, of a potential transaction
or matter that may be a business opportunity for both such Member or Manager and the Company or another Member or Manager, such
Member or Manager shall have no duty to communicate or offer such business opportunity to the Company or any other Member or Manager
and shall not be liable to the Company or the other Members or Managers for breach of any duty (including fiduciary duties) as
a Member or Manager by reason of the fact that such Member or Manager pursues or acquires such business opportunity for itself,
directs such opportunity to another Person, or does not communicate information regarding such opportunity to the Company.

 

(d)          For
the avoidance of doubt, all provisions with respect to Managers in this Section 3.6 shall be deemed to apply with equal
effect to any representative designated by a Member pursuant to Section 3.1(a)(v).

 

    8 

     

    

  

3.7           Indemnification
and Reimbursement for Payments on Behalf of a Member. If the Company becomes obligated to pay any taxes to a
governmental entity that are specifically attributable to a Member (including federal withholding taxes, state personal
property taxes, state personal property replacement taxes and state unincorporated business taxes), then such Person shall
indemnify the Company for such taxes. The Company may offset distributions to which a Member is otherwise entitled under this
Agreement against such Member’s obligation to indemnify the Company under this Section
3.7.          A Member’s obligation to indemnify the
Company under this Section 3.7 shall survive the termination, dissolution, liquidation and winding up of the Company,
and, for purposes of this Section 3.7, the Company shall be treated as continuing in existence. The Company may pursue
and enforce all rights and remedies it may have against each Member under this Section 3.7, including instituting
a lawsuit to collect such contribution with interest calculated at the Prime Rate.

 

3.8           Officers.         The
Company shall have such individuals as officers as may be appointed by the Board; provided, no officers are required to
be appointed. The officers of the Company may consist of any one or more of a Chief Executive Officer, President, one or more
Vice Presidents, a Secretary, one or more Assistant Secretaries, or such other officers as may be appointed by the Board. One
person may hold, and perform the duties of, any two or more of such offices. Any officer may be removed, with or without cause,
at any time by the Board. No officer need be a Member or Manager. Each officer shall be a “manager” (as that term
is used in the Act) of the Company, but, notwithstanding the foregoing, no officer shall have any rights or powers beyond the
rights and powers granted to such officer in this Agreement or by the Board from time to time and any such rights or powers may
be modified or withdrawn at any time and from time to time by the Board.

 

ARTICLE 4 

ACCOUNTING
AND REPORTING

 

4.1           Maintenance
of Books.

 

(a)          The
Company shall keep or cause to be kept at the principal office of the Company or at such other location approved by the Board complete
and accurate books and records of the Company, supporting documentation of the transactions with respect to the conduct of the
Company’s business, and any other books and records that are required to be maintained by applicable law.

 

(b)          The
books of account of the Company shall be maintained on the basis of a fiscal year ending as of June 30 unless, for U.S. federal
income tax purposes, another fiscal year is required.

 

4.2           Reports;
Access to Books and Records.

 

(a)          The
Company shall deliver to each Member:

 

(i)          with
respect to each Taxable Year, such income tax returns and such other accounting, tax information and schedules as shall be necessary
for the preparation by each Member of its income tax return with respect to such year, and shall use its reasonable best efforts
to do so on or before the first day of the third month following the end of such Taxable Year;

 

    9 

     

    

  

(ii)         to
the extent otherwise prepared by the Company, draft monthly income statements (promptly following the date such draft monthly
income statements are available) (provided that the Company shall not be required to prepare such draft monthly income
statements solely for the purposes of this Section 4.2(a)(ii));

 

(iii)        to
the extent otherwise prepared by the Company, unaudited monthly income statements and balance sheets, and any working papers or
supporting schedules as requested (promptly following the date such monthly financial statements are available) (provided that
the Company shall not be required to prepare such monthly financial statements solely for the purposes of this Section 4.2(a)(iii));

 

(iv)        unaudited
quarterly income statements, balance sheets, statements of changes in Members’ capital and statements of cash flow (within
45 days following the end of each of the first three fiscal quarters, and within 90 days following the end of the last fiscal quarter,
of each fiscal year);

 

(v)         annual
income statements, balance sheets, statements of changes in Members’ capital and statements of cash flow audited by the Company’s
outside auditor, if any (within 6 months following the end of each fiscal year);

 

(vi)        copies
of any forecasts (and modifications thereto) with respect to the Company prepared by or on behalf of the Company from time to
time (as promptly as reasonably practicable);

 

(vii)       monthly
reports prepared by the management of the Company that discuss relevant business conditions, trends, events and uncertainties;

 

(viii)      as
and when applicable, written notice of any litigation, securities laws, health and safety, risk management or other issues that
would be reasonably likely to have a material effect on the financial condition or operating performance of the Company (promptly
upon knowledge or occurrence of such circumstance); and

 

(ix)         such
other information as a Member or its Affiliates may reasonably request for accounting, Securities and Exchange Commission reporting
purposes or otherwise to comply with applicable law or the requirements of any governmental entity.

 

(b)  Without
limiting the foregoing, each Member shall have the right to inspect the books and records of the Company at reasonable times and
upon reasonable notice to the Board.

 

    10 

     

    

  

4.3           Bank
Accounts. Funds of the Company shall be deposited in such banks or other depositories as shall be designated from time to
time by the Board. All withdrawals from any such depository shall be made only as authorized by the Board and shall be made
only by check, wire transfer, debt memorandum or other written instruction.

 

ARTICLE 5

CAPITAL
CONTRIBUTIONS

 

5.1           Capital
Contributions. Each Member has made the Capital Contributions set forth on Exhibit A next to its name under the
heading “Initial Capital Contributions” (“Initial Capital Contributions”). No Member
shall be required to make any additional Capital Contributions without its consent, which may be withheld in its sole
discretion. The Board, however, may request that Members make additional Capital Contributions as may be required properly to
carry on the business of the Company. The Board will notify all Members of the request to make such additional Capital
Contributions, specifying the amount of and date upon which such contributions are requested, which date shall be not less
than thirty (30) days from the date of said notice. Any and all such additional Capital Contributions shall be requested of
each of the Members on a pro rata basis in accordance with the respective number of Units held by each Member at the
time such notice is given. If any Member elects not to provide its full pro rata portion of any additional Capital
Contributions requested pursuant to this Section 5.1, the other Members may make the additional Capital Contributions
that were requested of such Member, and the Units and percentage interests of the Members that have made additional Capital
Contributions and the Members that have not made additional Capital Contributions shall be adjusted accordingly to reflect
the additional Capital Contributions made by the contributing Members. In no event shall the Members be personally liable in
any manner to the Company for any additional Capital Contribution.

 

5.2           Return
of Contributions. Except as expressly provided herein, no Member shall be entitled, in connection with a withdrawal from
the Company or otherwise, to (a) the return of any part of its Capital Contributions, (b) any interest in respect of any
Capital Contribution, or

(c)          the
fair market value of its Units. Unrepaid Capital Contributions shall not be a liability of the Company or of any Member. No Member
shall be obliged to contribute or lend any cash or property to the Company to enable the Company to return any Member’s Capital
Contributions to the Company.

 

5.3           Member
Loans.  If the Company shall have insufficient cash to pay its obligations,
including because of an election by one or more Members not to make an additional Capital Contribution as contemplated by Section
5.1, any Member, with the approval of the Board and the Members, may, but shall not be obligated to, advance such funds for
the Company on such terms and conditions as the lending Member and the Board, with the approval of each of the Members, may determine.
Each such advance shall constitute a loan from such Member to the Company and shall not constitute a Capital Contribution.

 

    11 

     

    

  

5.4           Capital
Accounts. The Company will maintain a separate capital account (a “Capital
Account”) for each Member according to the rules of Treasury Regulations Section 1.704-1(b)(2)(iv). Each Member’s
Capital Account (i) will be increased by: (A) the amount of money contributed by such Member to the Company; (B) the initial Book
Value of property contributed by such Member to the Company (net of liabilities secured by the contributed property that the Company
is considered to assume or take subject to under Section 752 of the Code); (C) allocations to such Member of Profits pursuant
to Section 7.1 and any other items of income and gain pursuant to Sections 7.2 and 7.4; and (D) any other increases
allowed or required by Treasury Regulations Section 1.704-1(b)(2)(iv), and (ii) will be decreased by: (A) the amount of money
distributed to such Member by the Company; (B) the Book Value of property distributed to such Member by the Company (net of liabilities
secured by such distributed property that such Member is considered to assume or take subject to under Section 752 of the Code);
(C) allocations to such Member of Losses pursuant to Section 7.1 and any other items of losses and deductions pursuant
to Sections 7.2 and 7.4; and (D) any other decreases allowed or required by Treasury Regulations Section 1.704-1(b)(2)(iv).

 

ARTICLE 6

DISTRIBUTIONS

 

6.1           Distributions.
Except as otherwise provided herein and subject to any prohibition thereto, the Company shall annually distribute all of the most
recent fiscal year’s Available Cash. All such distributions to the Members shall be made pro rata based on the number
of Units held.

 

6.2           Successors.
For purposes of determining the amount of distributions hereunder, each Member shall be treated as having made the
Capital Contributions and as having received the distributions made to or received by its predecessors in respect of any of
such Member’s Units.

 

6.3           Right
of Set-Off.  The Company shall have the right to set off any amount
otherwise distributable to a Member pursuant to this Article 6 against any obligation of such Member to the Company and
such amounts will be treated as having been distributed to such Member for purposes of this Article 6.

 

ARTICLE 7

ALLOCATIONS
AND TAX MATTERS

 

7.1           Allocations
of Profits or Losses. After giving effect to the allocations provided in Sections 7.2 and 7.4, Profits and
Losses for each Taxable Year will be allocated among the Members during such Taxable Year in such a manner that, as of the
end of such Taxable Year, the sum of (a) the Capital Account of each such Member (as adjusted to reflect the allocations
under Section 7.2 and all distributions through the end of such Taxable Year), plus (b) such Member’s share of
Partnership Minimum Gain and Partner Nonrecourse Debt Minimum Gain (computed immediately prior to the hypothetical sale of
assets described below) and the amount such Member is treated as obligated to contribute to the Company (computed immediately
after the hypothetical sale of assets described below) will, to the greatest extent possible, be equal to the respective net
amount which would be distributed to such Member if the Company were to (i) sell all of the assets of the Company on hand at
the end of such Taxable Year for an amount of cash equal to their Book Values, (ii) all liabilities of the Company were
satisfied in cash in accordance with their terms (limited in the case of non-recourse liabilities to the Book Value of the
property securing such liabilities), and then (iii) all remaining or resulting cash was distributed to the Members pursuant
to Section 6.1.

 

    12 

     

    

  

7.2           Regulatory
Allocations. The following special allocations will be made in the following order of priority before allocations of
Profits and Losses:

 

(a)          If
there is a net decrease in Partnership Minimum Gain during any Taxable Year, each Member will be specially allocated items of
income and gain for that period (and, if necessary, for subsequent periods) in proportion to, and to the extent of, such Member’s
share of the net decrease in Partnership Minimum Gain during such Taxable Year, determined in accordance with Treasury Regulations
Section 1.704-2(g)(2). This Section 7.2(a) is intended to comply with the minimum gain chargeback requirement of Treasury
Regulations Section 1.704-2(f) and shall be interpreted consistently therewith.

 

(b)          If
there is a net decrease in Partner Nonrecourse Debt Minimum Gain during any Taxable Year, each Member will be specially
allocated items of income and gain for that period (and, if necessary, for subsequent periods) in proportion to, and to the
extent of, such Member’s share of the net decrease in Partner Nonrecourse Debt Minimum Gain during such Taxable Year,
determined in accordance with Treasury Regulations Section 1.704-2(i)(4). This Section 7.2(b) is intended to comply
with the partner nonrecourse debt minimum gain chargeback requirement of Treasury Regulations Section 1.704-2(i)(4) and shall
be interpreted consistently therewith.

 

(c)          No
Losses or other items of loss or expense shall be allocated to any Member to the extent that such allocation would cause such
Member to have a deficit balance in its Adjusted Capital Account (or increase any existing deficit balance in its Adjusted Capital
Account) at the end of such Taxable Year. All Losses and other items of loss and expense in excess of the limitation set forth
in this Section 7.2(c) shall be allocated to the Members who do not have a deficit balance in their Adjusted Capital Accounts
in proportion to their relative positive Adjusted Capital Accounts but only to the extent that such Losses and other items of
loss and expense do not cause any such Member to have a deficit in its Adjusted Capital Account.

 

(d)          Any
Member that unexpectedly receives an adjustment, allocation or distribution described in Treasury Regulations Section
1.704-1(b)(2)(ii)(d)(4), (5) and (6) shall be allocated items of income and gain (consisting of a pro rata portion of
each item of income, including gross income, and gain for the Taxable Year) in an amount and manner sufficient to eliminate
any deficit balance in such Member’s Adjusted Capital Account as quickly as possible; provided, however, that an
allocation pursuant to this Section 7.2(d) shall be made only if and to the extent that such Member would have a
deficit Adjusted Capital Account balance after all other allocations provided for in this Article 7 have been
tentatively made as if this Section 7.2(c) were not in this Agreement. This Section 7.2(c) is intended
to be a qualified income offset provision as described in Treasury Regulations Section 1.704-1(b)(2)(ii)(d) and will be
interpreted in a manner consistent therewith.

 

(e)          Nonrecourse
deductions (as defined in Treasury Regulations Section 1.704-2(c)) for any Taxable Year will be allocated among the Members in
proportion to their respective Units.

 

    13 

     

    

  

(f)          Partner
Nonrecourse Deductions for any Taxable Year will be allocated to the Member or Members who bear the economic risk of loss with
respect to the partner nonrecourse debt (as defined in Treasury Regulations Sections 1.704-2(b)(4) and 1.752-2) to which the Partner
Nonrecourse Deductions are attributable in accordance with Treasury Regulations Section 1.704-2(i).

 

(g)          To
the extent an adjustment to the adjusted tax basis of any Company properties pursuant to Code Section 734(b) (including any such
adjustment pursuant to Treasury Regulations Section 1.734-2(b)(1)) is required pursuant to Treasury Regulations Section 1.704-1(b)(2)(iv)(m)(2)
or 1.704-1(b)(2)(iv)(m)(4) to be taken into account in determining Capital Accounts as the result of a distribution to any Member
in complete liquidation of such Member’s interest in the Company, the amount of such adjustment to Capital Accounts shall
be treated as an item of gain (if the adjustment increases the basis of the asset) or loss (if the adjustment decreases such basis)
and such gain or loss shall be allocated to the Members in accordance with Treasury Regulations Section 1.704-1(b)(2)(iv)(m)(2)
if such Treasury Regulations Section applies, or to the Member to whom such distribution was made if Treasury Regulations Section
1.704-1(b)(2)(iv)(m)(4) applies.

 

7.3           Tax
Allocations.

 

(a)          Except
as otherwise provided in this Section 7.3, all items of income, gains, losses, deductions and credits of the Company for federal,
state and local income tax purposes will be allocated among the Members in the same manner as the corresponding item is allocated
pursuant to Sections 7.1, 7.2 and 7.4.

 

(b)          Items
of Company taxable income, gain, loss and deduction with respect to any property contributed to the Company will be allocated
among the Members in accordance with Code Section 704(c) and the applicable Treasury Regulations so as to take account of any
variation between the adjusted basis of such property to the Company for federal income tax purposes and its initial Book Value
and the applicable Treasury Regulations thereunder. For purposes of such allocations, the Members agree to work together in good
faith to consider adopting the remedial allocation method described in Treasury Regulations Section 1.704-3(d), or the traditional
method with curative allocations described in Treasury Regulations Section 1.704-3(c), but further agree that the Company may
adopt either such method only upon the approval of both Members.

 

(c)          If
the Book Value of any Company asset is adjusted pursuant to clause (b) or (d) of the definition of “Book
Value,” subsequent allocations of items of taxable income, gain, loss and deduction with respect to such asset will
take account of any variation between the adjusted basis of such asset for federal income tax purposes and its Book Value in
the same manner as under Code Section 704(c).

 

(d)          Any
recapture of depreciation, or any other item of deduction shall be allocated, in accordance with Treasury Regulations Sections
1.1245-1(e) and 1.1254-5, to the Members who received the benefit of such deductions (taking into account the effect of remedial
allocations).

 

    14 

     

    

  

(e)          Tax
credits, tax credit recapture, and any items related thereto will be allocated to the Members as provided in Treasury Regulations
Sections 1.704-1(b)(4)(ii) and 1.704-1(b)(4)(viii).

 

(f)          Allocations
pursuant to this Section 7.3 are solely for purposes of federal, state and local taxes and, except as otherwise
specifically provided, will not affect, or in any way be taken into account in computing any Member’s Capital Account
or share of Profits, Losses, distributions or other Company items pursuant to any provision of this Agreement.

 

7.4           Curative
Allocations. The allocations set forth in Section 7.2 (the “Regulatory Allocations”) are
intended to comply with certain requirements of Treasury Regulations Sections 1.704-1(b) and 1.704-2. The Regulatory
Allocations may not be consistent with the manner in which the Members intend to allocate Profit and Loss of the Company or
make distributions. It is the intent of the Members that, to the extent possible, all Regulatory Allocations shall be offset
either with other Regulatory Allocations or with special allocations of other items of Company income, gain, loss or
deduction pursuant to this Section 7.4. Accordingly, notwithstanding any other provision of this Article 7 (other
than the Regulatory Allocations), but subject to the Code and the Treasury Regulations, the Board will make such offsetting
special allocations of Company income, gain, deduction, or loss in whatever manner it determines appropriate so that, after
such offsetting allocations are made, each Member’s Capital Account balance is, to the extent possible, equal to the
Capital Account balance such Member would have had if the Regulatory Allocations had not been made. In making such
determination, the Board shall take into account future Regulatory Allocations that, although not yet made, are likely to
offset other Regulatory Allocations previously made.

 

7.5           Other
Allocation Rules.

 

(a)          All
items of income, gain, loss, deduction and credit allocable to an interest in the Company that may have been transferred shall
be allocated between the transferor and the transferee based on the “interim closing method” under Code Section 706
and the Treasury Regulations thereunder or such other method determined by the Members and permissible under Code Section 706 and
the Treasury Regulations thereunder, without regard to whether cash distributions were made to the transferor or the transferee
during that year.

 

(b)          The
Members’ proportionate shares of the “excess nonrecourse liabilities” of the Company, within the meaning of
Treasury Regulations Section 1.752-3(a)(3), shall be allocated among the Members pro rata based on the number of Units
held.

 

(c)          The
definition of “Capital Account” set forth in Section 5.4 and the allocations set forth in Sections
7.2, 7.3, and 7.4 and the preceding provisions of this Section 7.5 are intended to comply with
the Treasury Regulations. If the Board and each of the Members determines that the determination of a Member’s Capital
Account or the allocations to a Member are not in compliance with the Treasury Regulations, the Board is authorized to make
any appropriate adjustments.

 

    15 

     

    

  

7.6           Tax
Returns. The Company shall cause to be prepared and filed all necessary federal and state income tax returns for the
Company, including making the elections described in Section 7.7.   Each Member shall furnish to the
Company all pertinent information in its possession relating to Company operations that is necessary to enable such income
tax returns to be prepared and filed. Not less than sixty (60) days prior to the due date (as extended) of the
Company’s federal income tax return or any state income tax return, the return proposed to be filed by the
Company shall be furnished to each of the Members for review. Not more than ten (10) days after the date on which the Company
files its federal income tax return or any state income tax return, a copy of the return so filed shall be furnished to the
Members. In addition, the Company shall use its reasonable best efforts to cause Schedule K-1s to be delivered to each Member
on or before the first day of the third month following the end of the previous Taxable Year.

 

7.7           Tax
Elections. The following elections shall be made on the appropriate returns of the Company:

 

(a)          to
adopt the Company’s fiscal year in accordance with Section 4.1(b);

 

(b)          to
adopt the accrual method of accounting and to keep the Company’s books and records on the income-tax method;

 

(c)          if
there is a distribution of Company property as described in Section 734 of the Code or if there is a transfer of a Company interest
as described in Section 743 of the Code, upon written request of any Member and the consent of the Board and each of the Members,
to elect, pursuant to Section 754 of the Code, to adjust the basis of Company properties;

 

(d)          to
elect to amortize the organizational expenses of the Company ratably over a period of 180 months as permitted by Section 709(b)
of the Code; and

 

(e)          any
other election the Board with the approval of each of the Members may deem appropriate and in the best interests of the Members.

 

No election shall be
made by the Company or any Member to exclude the Company from the application of the provisions of subchapter K of chapter 1 of
subtitle A of the Code or any similar provisions of applicable state laws or to be classified as other than a partnership pursuant
to Treasury Regulations Section 301.7701-3.

 

7.8           Tax
Matters Member. iBio shall be the “tax matters partner” of the Company pursuant to Section 6231(a)(7) of the Code
and Section 301.6231(a)(7)-2 of the Treasury Regulations (the “Tax Matters Member”) and the Partnership Representative.
The Tax Matters Member shall take such action as may be necessary to cause each other Member to become a “notice partner”
within the meaning of Section 6223 of the Code. The Tax Matters Member shall inform each other Member of all significant matters
that may come to its attention in its capacity as the Tax Matters Member by giving notice thereof within ten (10) days after becoming
aware thereof and, within such time, shall forward to each other Member copies of all significant written communications it may
receive in such capacity. This provision is not intended to authorize the Tax Matters Member to take any action left to the determination
of an individual Member under Sections 6222 through 6231 of the Code. Notwithstanding the foregoing, the Tax Matters Member shall
not (i) enter into any extension of the period of limitations for making assessments on behalf of the Members without first obtaining
the written consent of each of the Members, or (ii) bind the Members to a settlement agreement without obtaining the written consent
of each of the Members.

 

    16 

     

    

 

ARTICLE 8

WITHDRAWAL, DISSOLUTION,
LIQUIDATION AND TERMINATION

 

8.1           Dissolution,
Liquidation, and Termination Generally. The Company shall begin an orderly dissolution on the first to occur of any of the
following:

 

(a)          the
election of the Board, with the consent of each of the Members; or

 

(b)          the
occurrence of any event which, as a matter of law, requires that the Company be dissolved.

 

8.2           Liquidation
and Termination. Upon dissolution of the Company, the Board, with the consent of each of the Members, shall appoint one
or more qualified Persons as liquidator (which may be a Member). The liquidator shall proceed diligently to wind up the
affairs of the Company and make final distributions as provided herein. The costs of liquidation shall be a Company expense.
Until final distribution, the liquidator shall continue to operate the Company properties with all of the power and authority
of the Board hereunder. The steps to be accomplished by the liquidator are as follows:

 

(a)          as
promptly as possible after dissolution and again after final liquidation, the liquidator shall cause a proper accounting to be
made by a firm of certified public accountants acceptable to each of the Members of the Company’s assets, liabilities, and
operations through the last day of the calendar month in which the dissolution shall occur or the final liquidation shall be completed,
as applicable;

 

(b)          the
liquidator shall pay all of the debts and liabilities of the Company or otherwise make adequate provision therefor (including
the establishment of a cash escrow fund for contingent liabilities in such amount and for such term as the liquidator may reasonably
determine); and

 

(c)          all
remaining assets of the Company shall be distributed to the Members in accordance with Section 6.1.

 

8.3           Deficit
Capital Accounts. No Member shall be required to pay to the Company, to any other Member or to any third party any
deficit balance in such Member’s Capital Account which may exist from time to time in any capital or similar account
maintained for such Member for any purpose.

 

8.4           Cancellation
of Certificate. On completion of the distribution of Company assets, a Member authorized by the Board (or such other Person
as the Act may require or permit) shall file a Certificate of Cancellation with the Secretary of State of the State of Delaware,
cancel any other filings made pursuant to Section 1.4, and take such other actions as may be necessary to terminate the
existence of the Company.

 

    17 

     

    

 

8.5           Reasonable
Time for Winding Up. A reasonable time shall be allowed for the orderly winding up of the business and affairs of the
Company and the liquidation of its assets pursuant to Section 8.2 to minimize any losses otherwise attendant upon such
winding up.

 

8.6           Return
of Capital. The liquidator shall not be personally liable for the return of Capital Contributions or any portion thereof to
the Members (it being understood that any such return shall be made solely from Company assets).

 

8.7           Antitrust
Laws. Notwithstanding any other provision in this Agreement, in the event that any Antitrust Law is applicable to any
Member by reason of the fact that any assets of the Company shall be distributed to such Member in connection with the
winding up of the Company, such distribution shall not be consummated until such time as the applicable waiting periods (and
extensions thereof) under such Antitrust Law have expired or otherwise been terminated with respect to each such Member.

 

8.8           Other
Remedies. Nothing in this Article 8 shall limit any Member’s
right to enforce any provision of this Agreement by an action at law or equity, nor shall an election to dissolve the Company pursuant
to this Article 8 relieve any Member of any liability for any prior or subsequent breach of this Agreement or another document
referred to herein.

 

ARTICLE 9

MISCELLANEOUS
PROVISIONS

 

9.1           Confidentiality.
Subject to Section 9.12, by executing this Agreement (or any counterpart or joinder hereto), each Member expressly agrees
to maintain the confidentiality of, and not to divulge, communicate, use to the detriment of the Company or any of its Affiliates
for the benefit of any other Person, or misuse in any way, or disclose to any Person other than the Company, any of its subsidiaries,
another Member or a Person designated by the Company or any of their respective financial planners, accountants, attorneys or other
advisors who are bound by obligations of confidentiality, any information relating to the business, financial structure, financial
position or financial results, technology or other assets, clients or affairs of the Company or any of its subsidiaries, or any
other confidential or proprietary information (including any trade secrets or other intellectual property) of the Company or any
of its subsidiaries, except for a purpose relevant to or in furtherance of this Agreement (including at the direction of the Board)
or as otherwise required by law or by any regulatory or self-regulatory organization having jurisdiction (with prior notice to
the Company (to the extent permitted under applicable law or regulation) and, if requested by the Company, seeking confidential
treatment where reasonably available).       This Section 9.1 shall not apply to any
information that is or has become generally available to the public without a breach of this Section 9.1 by, or any other
action or inaction of, the disclosing Member. Each Member hereby acknowledges and agrees that any information such Member has acquired
on any of these matters or items were received in confidence. Without limiting Section 9.14 or Section 9.15, each
Member hereby further acknowledges and agrees that the Company would be irreparably damaged by reason of any violation of the provisions
of this Section 9.1, and that any remedy at law for a breach of such provisions would be inadequate. Therefore, the Company
shall be entitled to seek and obtain injunctive or other equitable relief (including a temporary restraining order, temporary injunction
or permanent injunction) against any Member or such Member’s agents, successors or assigns for any breach or threatened or
anticipated breach of such provisions and without the necessity of proving actual monetary loss. It is hereby acknowledged and
agreed by the Members that this injunctive or other equitable relief shall not be the Company’s exclusive remedy for any
breach of this Section 9.1 and that the Company shall be entitled to seek any other relief or remedy that it may have by
contract, statute, law or otherwise for any breach hereof, and it is agreed that the Company shall also be entitled to recover
its attorneys’ fees and expenses in any successful action or suit against any Member relating to any such breach.

 

    18 

     

    

 

9.2           Notices. All
notices or other communications provided for or permitted to be given pursuant to this Agreement shall be in writing and
shall be deemed to have been duly given or made (a) upon delivery if delivered personally (by courier service which tracks
deliveries or otherwise), (b) upon delivery if sent by email before 5:00 p.m. (local time of the recipient) on a Business
Day, or, if not, then on the next Business Day or (c) upon confirmation of dispatch if sent by facsimile transmission (which
confirmation shall be sufficient if shown on the journal produced by the facsimile machine used for such transmission) before
5:00 p.m. (local time of the recipient) on a Business Day, or, if not, then on the next Business Day, and all legal process
with regard hereto shall be validly served when served in accordance with applicable law, in each case to the applicable
addresses set forth on Exhibit A (or such other address as the recipient may specify in accordance with this Section),
or, with respect to notices to the Company, to the Company’s principal office set forth in Section 1.3.

 

9.3           Entireties;
Amendments. This Agreement, the Subscription Agreement and the other agreements expressly contemplated hereby constitute
the entire agreement between the Members relative to the formation of the Company and the terms and conditions set forth
herein. The Company and each Member acknowledge and agree that, except for the representations and warranties made by the
Members as expressly set forth in this Agreement, the Subscription Agreement and the other agreements expressly contemplated
hereby, none of the Members or any of their respective Affiliates or representatives makes or has made to the Company, any
Member or any of their respective Affiliates or representatives any representation or warranty of any kind. Any amendment to
this Agreement shall be effective only if set forth in a writing duly executed by each of the Members.

 

9.4           Waiver.
Any waiver of any right or obligation under this Agreement shall be effective only if set forth in a writing duly executed by the
Member against whom the waiver is to be enforced. No consent or waiver, express or implied, by any Member of any breach or default
by any other Member in the performance by the other Member of its obligations hereunder shall be deemed or construed to be a consent
or waiver to or of any other breach or default in the performance by such other Member (or any other Member) of the same or any
other obligation hereunder. Failure on the part of any Member to complain of any act or to declare any other Member in default,
irrespective of how long such failure continues, shall not constitute a waiver of rights hereunder.

 

    19 

     

    

 

9.5           Severability.
If any provision of this Agreement or the application thereof to any Person or circumstances shall be invalid or unenforceable
to any extent, and such invalidity or unenforceability does not destroy the basis of the bargain between the parties, then the
remainder of this Agreement and the application of such provisions to other Persons or circumstances shall not be affected thereby
and shall be enforced to the greatest extent permitted by law.

 

9.6           Ownership
of Property and Right of Partition. A Member’s interest in the
Company shall be personal property for all purposes. All property of the Company, whether tangible or intangible, shall be deemed
to be owned by the Company as an entity. No Member shall have any interest in specific Company property solely by reason of being
a Member. Except as specifically contemplated by this Agreement or any other written agreement between the Company and any Member,
no Member shall (a) have the right to seek or obtain partition by court decree or operation of law of any property of the Company
or any of its subsidiaries, (b) have the right to own or use particular or individual assets of the Company or any of its subsidiaries,
or (c) be entitled to distributions of specific assets of the Company or any of its subsidiaries.

 

9.7           Involvement
of Members in Certain Proceedings. Should any Member become involved in legal proceedings unrelated to the Company’s
business in which the Company is required to provide books, records, an accounting, or other information, then such Member shall
indemnify the Company against all expenses incurred in conjunction therewith.

 

9.8           Interest.         No
amount charged as interest on loans hereunder shall exceed the maximum rate from time to time allowed by applicable law. No amount
charged as interest on debt instruments as defined in Section 1274(c) of the Code shall be less than the minimum applicable federal
rate as defined in Section 1274(d) of the Code.

 

9.9           Counterparts.
This Agreement may be signed in counterparts, which need not contain the signature of more than one party, but taken together shall
constitute one and the same agreement.

 

9.10         No
Third Party Beneficiaries. This Agreement is entered into solely for
the benefit of the Members and no Person other than the Members, their respective successors and permitted assigns, their Affiliates
to the extent expressly provided herein, and (to the extent provided in Section 3.5) the Persons entitled to indemnification
pursuant to Section 3.5, may exercise any right or enforce any obligation hereunder.

 

9.11         Further
Assurances.         Each Member shall execute and deliver such further documents
and take such further actions as any other Member may reasonably request consistent with the provisions hereof in order to effect
the intent and purposes of this Agreement.

 

9.12         Public
Statements; Press Release. No Member shall issue any press releases or otherwise make any public statements with respect to
this Agreement or the transactions contemplated hereby without the prior written consent of the Board and the other Members, except
as may be required by law and, to the extent practicable, after consultation with the Board and the other Members. Notwithstanding
the foregoing and Section 9.1, any Member may make any disclosures regarding this Agreement or the Company required by applicable
securities law or the rules and regulations of the Securities and Exchange Commission or any exchange on which such Member’s
securities are listed, including filing this Agreement with the Securities and Exchange Commission; provided that such Member
shall consult with the Board and the other Members prior to any such disclosure to the extent practicable. Any such press release
or public statement must also comply with any agreement to which the Company is a party or by which it is bound.

 

    20 

     

    

 

9.13         Delivery
by Facsimile or Email. This Agreement, the agreements referred to herein,
and each other agreement or instrument entered into in connection herewith or therewith or contemplated hereby or thereby, and
any amendments hereto or thereto, to the extent signed and delivered by means of a facsimile machine or email with scan or facsimile
attachment, shall be treated in all manner and respects as an original agreement or instrument and shall be considered to have
the same binding legal effect as if it were the original signed version thereof delivered in person. At the request of any party
hereto or to any such agreement or instrument, each other party hereto or thereto shall re-execute original forms thereof and
deliver them to all other parties. No party hereto or to any such agreement or instrument shall raise the use of a facsimile machine
or email to deliver a signature or the fact that any signature or agreement or instrument was transmitted or communicated through
the use of a facsimile machine or email as a defense to the formation or enforceability of a contract, and each such party forever
waives any such defense.

 

9.14         Governing
Law; Dispute Resolution.

 

(a)          This
Agreement shall be governed by and construed in accordance with the laws of the State of New York, U.S.A., without regard to conflicts
of laws provisions.

 

(b)          In
the event of any dispute, controversy, or claim arising out of, relating to, or in connection with this Agreement, or the breach,
termination, or validity thereof, between the Members, the Members will first attempt in good faith to resolve such dispute by
negotiation and consultation between themselves. In the event that such dispute is not resolved on an informal basis within twenty
(20) days, any Member may, by written notice to the other, have such dispute referred to the Chief Executive Officer of each Member,
or his or her designee (who will be a senior executive), who will attempt in good faith to resolve such dispute by negotiation
and consultation for a thirty (30) day period following receipt of such written notice.

 

(c)          In
the event the Members are not able to resolve such dispute through the negotiation and consultation procedures set forth in Section
9.14(b), any Member may at any time after the applicable negotiation and consultation period submit such dispute to be finally
settled by arbitration administered by the American Arbitration Association (the “AAA”), including the AAA’s
Procedures for Large, Complex Commercial Disputes, in effect at the time of the arbitration, except as they may be modified herein
or by agreement of each of the Members. The seat of the arbitration shall be New York, New York, and it shall be conducted in the
English language. The arbitration and this clause shall be governed by Title 9 (Arbitration) of the United States Code.

 

    21 

     

    

 

(d)         The
arbitration shall be conducted by three arbitrators. The claimant shall appoint an arbitrator in its request for arbitration.
The respondent shall appoint an arbitrator within 20 days of the receipt of the request for arbitration. The two arbitrators shall
appoint a third arbitrator, who shall act as chair of the tribunal, within 20 days after the appointment of the second arbitrator.
If any of the three arbitrators is not appointed within the time prescribed above, then the AAA shall appoint that arbitrator
from its National Panel of Securities Arbitrators or its Large, Complex Commercial Case Panel, not including any such members
affiliated with the securities industry. The chair of the tribunal shall be a citizen of the United States.

 

(e)          In
addition to the authority conferred on the arbitration tribunal by the applicable rules, the arbitration tribunal shall have the
authority to order such production of documents, generally consistent with the discovery permitted under the Federal Rules of Civil
Procedure, as may reasonably be requested by any party or by the tribunal itself. In addition, any party may request a reasonable
number of depositions of Member witnesses.

 

(f)          The
Members agree that the arbitration shall be kept confidential and that the existence of the proceeding and any element of it (including
but not limited to any pleadings, briefs or other documents submitted or exchanged, any testimony or other oral submissions, and
any awards) shall not be disclosed beyond the tribunal, the AAA, the parties, their counsel, accountants and auditors, insurers
and re-insurers, and any Person necessary to the conduct of the proceeding. The confidentiality obligations shall not apply (i)
if disclosure is required by law, or in judicial or administrative proceedings, or (ii) as far as disclosure is necessary to enforce
the rights arising out of the award.

 

(g)          The
arbitration award shall be final and binding on the parties. Judgment upon the award may be entered by any court having jurisdiction
thereof or having jurisdiction over the relevant Member or its assets.

 

(h)         In
order to facilitate the comprehensive resolution of related disputes, and upon request of any Member that is party to the arbitration
proceeding, the arbitration tribunal may consolidate the arbitration proceeding with any other arbitration proceeding involving
any of the Members relating to this Agreement. The arbitration tribunal shall not consolidate such arbitrations unless it determines
that (i) there are issues of fact or law common to the related proceedings so that a consolidated proceeding would be more efficient
than separate proceedings, and (ii) no Member would be prejudiced as a result of such consolidation through undue delay or otherwise.

 

9.15         Remedies
Cumulative; Specific Performance. The rights and remedies of the Members hereunder shall be cumulative (and not alternative).
The Members agree that, in the event of any breach or threatened breach by any Member of any covenant, obligation or other provision
set forth in this Agreement, for the benefit of each other Member: (a) such other Member shall be entitled (in addition to any
other remedy that may be available to it) to (i) a decree or order of specific performance or mandamus to enforce the observance
and performance of such covenant, obligation or other provision, and (ii) an injunction restraining such breach or threatened breach;
and (b) such other Member shall not be required to provide any bond or other security in connection with any such decree, order
or injunction or in connection with any related action or legal proceeding.

 

    22 

     

    

 

9.16         Ratification
of Certain Agreements and Transactions. For the avoidance of doubt, the Members hereby acknowledge and approve, ratify and
confirm in all respects the execution and delivery of the following agreements by iBio, for and on behalf of the Company, and the
Company’s entry into and performance of the transactions contemplated by such agreements, in each case as the authorized
acts and deeds of the Company: (a) that certain Sublease Agreement, dated on or after the date hereof, between the Company and
College Station Investors LLC, a Texas limited liability company (“CSI”); (b) that certain Memorandum of Sublease,
dated on or after the date hereof, between the Company and CSI; (c) that certain Termination of Temporary Right of Entry Agreement
– Personal Property, dated on or after the date hereof, between the Company and CSI; and (d) that certain Termination of
Temporary Right of Entry Agreement – Real Property, dated on or after the date hereof, between the Company and CSI.

 

ARTICLE 10

DEFINITIONS;
CONSTRUCTION

 

10.1         Definitions.         As
used in this Agreement, the following terms shall have the following meanings:

 

“AAA”
has the meaning set forth in Section 9.14(c).

 

“Act”
means the Delaware Limited Liability Company Act, as it may be amended from time to time.

 

“Adjusted
Capital Account” means the Capital Account maintained for each Member, (i) increased by any amounts that such Member
is obligated to restore (or is treated as obligated to restore under Treasury Regulations Sections 1.704-1(b)(2)(ii)(c), 1.704-2(g)(1)
and 1.704- 2(i)(5)), and (ii) decreased by any amounts described in Treasury Regulations Section 1.704- 1(b)(2)(ii)(d)(4), (5)
or (6) with respect to such Member. The foregoing definition of “Adjusted Capital Account” is intended to comply with
the provisions of Treasury Regulations Sections 1.704-1(b)(2)(ii)(d) and 1.704-2 and shall be interpreted consistently therewith.

 

“Affiliate”
means, with respect to any Person, another Person who directly, or indirectly through one or more intermediaries, Controls, is
Controlled by, or is under common Control with such first Person, and with respect to any Person who is an individual, any member
of such individual’s family group (defined as such individual’s spouse, siblings and descendants (whether natural or
adopted), any trust, limited partnership or limited liability company established solely for the benefit of such individual or
such individual’s spouse, siblings or descendants, and any executor or trustee of such individual’s estate). Any Person
who is (or Controls) the general partner of a partnership or the managing member of a limited liability company shall be deemed
an Affiliate of such partnership or limited liability company.

 

“Agreement”
has the meaning for such term set forth in the introductory paragraph hereof.

 

“Antitrust
Law” means any law relating to the preservation of or restraint against competition in commercial activities, including
the United States Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended.

 

    23 

     

    

 

“Available
Cash” means all cash, revenues and funds received by the Company from Company operations for the applicable fiscal year,
less the sum of the following, to the extent paid or set aside by the Company for such fiscal year: (i) all principal and interest
payments on indebtedness of the Company and all other sums paid to lenders (including in connection with any loans to Members contemplated
by Section 5.3); (ii) all cash expenditures (including Capital Expenditures) incurred in the operation of the Company’s
business; and (iii) reserves that the Board may from time to time determine are required or are reasonably appropriate to be retained
as of the end of the fiscal year to meet any accrued or foreseeable expenses, expenditures (including Capital Expenditures), liabilities,
or other obligations of the Company.

 

“Board”
has the meaning set forth in Section 3.1.

 

“Book Value”
means, with respect to any Company property, such property’s adjusted basis for U.S. federal income tax purposes, except
as follows:

 

(i)          The
initial Book Value of any property contributed by a Member to the Company shall be the fair market value of such property as of
the date of such contribution, as determined in good faith by the Board;

 

(ii)         The
Book Values of all properties shall be adjusted to equal their respective fair market values, as determined in good faith by the
Board, in connection with (A) the acquisition of an interest (or an additional interest) in the Company by any new or existing
Member in exchange for more than a de minimis Capital Contribution to the Company or in exchange for the performance
of more than a de minimis amount of services to or for the benefit of the Company, (B) the distribution by the Company
to a Member of more than a de minimis amount of property as consideration for an interest in the Company, (C) the
liquidation of the Company within the meaning of Treasury Regulations Section 1.704-1(b)(2)(ii)(g)(1) (other than pursuant to Section
708(b)(1)(B) of the Code, (D) the acquisition of an interest in the Company by any new or existing Member upon the exercise of
a noncompensatory option in accordance with Treasury Regulations Section 1.704-1(b)(2)(iv)(s), or (E) any other event
to the extent determined by the Board with the approval of each of the Members to be permitted and necessary to properly reflect
Book Values in accordance with the standards set forth in Treasury Regulations Section 1.704-1(b)(2)(iv)(q); provided, however,
that adjustments pursuant to clauses (ii)(A), (ii)(B) and (ii)(D) above shall be made only if the Board with
the approval of each of the Members determines that such adjustments are necessary or appropriate to reflect the relative economic
interests of the Member in the Company. If any noncompensatory options are outstanding upon the occurrence of an event described
in clauses (ii)(A) through (ii)(E) above, the Company shall adjust the Book Values of its properties in accordance
with Treasury Regulations Sections 1.704-1(b)(2)(iv)(f)(1) and 1.704- 1(b)(2)(iv)(h)(2);

 

    24 

     

    

 

(iii)        The
Book Value of property distributed to a Member shall be adjusted to equal the fair market value of such property as of the date
of such distribution, as determined in good faith by the Board; and

 

(iv)        The
Book Value of all property shall be increased (or decreased) to reflect any adjustments to the adjusted basis of such property
pursuant to Code Section 734(b) (including any such adjustments pursuant to Treasury Regulations Section 1.734-2(b)(1)), but only
to the extent that such adjustments are taken into account in determining Capital Accounts pursuant to Treasury Regulations Section
1.704-1(b)(2)(iv)(m) and clause (vi) of the definition of “Profits” or “Losses” or Section 7.2(e);
provided, however, that the Book Value of property shall not be adjusted pursuant to this clause (iv) to the extent
that the Board with the approval of each of the Members determines that an adjustment pursuant to clause (ii) hereof is
necessary or appropriate in connection with a transaction that would otherwise result in an adjustment pursuant to this clause
(iv).

 

If the Book Value of
property has been determined or adjusted pursuant to clauses (i), (ii) or (iv) hereof, such Book Value shall
thereafter be adjusted by the Depreciation taken into account with respect to such property for purposes of computing items allocated
pursuant to Section 7.1 through Section 7.4.

 

“Bryan”
has the meaning set forth in Section 2.2.

 

“Business
Day” means any day other than Saturday, Sunday, or other day on which commercial banks in New York, New York are authorized
or required to close under the laws of the State of New York.

 

“Capital
Account” has the meaning set forth in Section 5.4.

 

“Capital
Contribution” means, with respect to each Member, the amount of cash, cash equivalents, promissory obligations
(other than promissory obligations of the contributing Member) or the initial Book Value of any other property that such
Member contributes to the Company with respect to any Unit. Any reference in this Agreement to the Capital Contribution of a
Member shall include a Capital Contribution of its predecessors in interest.

 

“Capital Expenditure”
means an expenditure (whether paid in cash or accrued as a liability) that, in accordance with generally accepted accounting principles,
is (or is required to be) included in the property, plant and equipment reflected on the Company’s balance sheet.

 

“Certificate”
has the meaning for such term set forth in Section 1.1.

 

“Change in
Control” means, with respect to any Person, any event that causes such Person to cease to be Controlled by such Person’s
Controlling Person(s) as of the date of this Agreement.

 

    25 

     

    

 

“Code”
means the United States Internal Revenue Code of 1986, as amended from time to time. All references herein to Sections of the Code
will be deemed to include any corresponding provisions of succeeding law.

 

“Company”
has the meaning for such term set forth in the introductory paragraph hereof.

 

“Control,”
including the correlative terms “Controlling,” “Controlled,” and “under common Control with,”
means the right to exercise, directly or indirectly, more than fifty percent (50%) of the voting rights in a Person or possession
of the power to direct or cause the direction of the management or policies of the Controlled Person, whether through the ownership
of voting securities, contract or otherwise.

 

“CSI”
has the meaning set forth in Section 9.16.

 

“Depreciation”
means, for each Taxable Year, an amount equal to the depreciation, amortization or other cost recovery deduction
allowable for U.S. federal income tax purposes with respect to property for such Taxable Year, except that: (i) with respect
to any such property the Book Value of which differs from its adjusted tax basis for U.S. federal income tax purposes and
which difference is being eliminated by use of the “remedial method” pursuant to Treasury Regulations Section
1.704 3(d), Depreciation for such Taxable Year shall be the amount of book basis recovered for such Taxable Year under the
rules prescribed by Treasury Regulations Section 1.704 3(d)(2); and (ii) with respect to any other such property the Book
Value of which differs from its adjusted tax basis at the beginning of such Taxable Year, Depreciation shall be an amount
which bears the same ratio to such beginning Book Value as the U.S. federal income tax depreciation, amortization, or other
cost recovery deduction for such Taxable Year bears to such beginning adjusted tax basis; provided, however, that if
the adjusted tax basis of any property at the beginning of such Taxable Year is zero dollars ($0.00), Depreciation with
respect to such property shall be determined with reference to such beginning value using any reasonable method selected by
the Board with the approval of each of the Members.

 

“Encumbrance”
has the meaning for such term set forth in Section 2.2.

 

“iBio”
has the meaning set forth in Section 2.2.

 

“Indemnified
Party” has the meaning for such term set forth in Section 3.5.

 

“Members”
means those individuals and entities listed on Exhibit A hereto, and each Person hereafter admitted as a Member in accordance
with this Agreement, until such Person ceases to be a Member of the Company.

 

“Partner Nonrecourse
Debt Minimum Gain” has the meaning assigned to it in Treasury Regulations Section 1.704-2(i)(2).

 

“Partner Nonrecourse
Deductions” has the meaning assigned to it in Treasury Regulations Section 1.704-2(i)(2).

 

    26 

     

    

 

“Partnership
Minimum Gain” has the meaning assigned to it in Treasury Regulations Sections 1.704-2(b)(2) and 1.704-2(d).

 

“Partnership
Representative” has the meaning assigned to that term in Section 6223 of the Code and any Treasury Regulations or other
administrative or judicial pronouncements promulgated thereunder.

 

“Person”
means an individual or entity.

 

“Prime Rate”
means the highest prime rate (or base rate) reported in the Money Rate column or section of The Wall Street Journal, from
time to time, as having been the rate in effect for corporate loans at large United States money center commercial banks (whether
or not such rate has actually been charged by any such bank). If The Wall Street Journal ceases publication of the Prime
Rate, the “Prime Rate” shall mean the highest rate charged by such banks on short-term, unsecured loans to its most
creditworthy large corporate borrowers.

 

“Profits”
or “Losses” means, for each Taxable Year, an amount equal to the Company’s taxable income or loss
for such period, determined in accordance with Code Section 703(a) (for this purpose, all items of income, gain, loss,
or deduction required to be stated separately pursuant to Code Section 703(a)(1) shall be included in taxable income or
loss), with the following adjustments (without duplication):

 

(i)          any
income of the Company that is exempt from U.S. federal income tax and not otherwise taken into account in computing Profits and
Losses pursuant to this definition of “Profits” or “Losses” shall be added to such taxable income or loss;

 

(ii)         any
expenditures of the Company described in Code Section 705(a)(2)(B) or treated as Code Section 705(a)(2)(B) expenditures pursuant
to Treasury Regulations Section 1.704-1(b)(2)(iv)(i) and not otherwise taken into account in computing Profits or Losses pursuant
to this definition of “Profits” or “Losses” shall be subtracted from such taxable income or loss;

 

(iii)        if
the Book Value of any Company property is adjusted pursuant to clause (ii) or (iii) of the definition of “Book
Value,” the amount of such adjustment will be treated as an item of gain (if the adjustment increases the Book Value of
the asset) or an item of loss (if the adjustment decreases the Book Value of the asset) from the disposition of such asset and
will be taken into account for purposes of computing the amounts to be allocated pursuant to Section 7.1;

 

(iv)        gain
or loss resulting from any disposition of property with respect to which gain or loss is recognized for U.S. federal income tax
purposes shall be computed by reference to the Book Value of the property disposed of, notwithstanding that the adjusted tax basis
of such property differs from its Book Value;

 

(v)         in
lieu of the depreciation, amortization, and other cost recovery deductions taken into account in computing such taxable income
or loss, there shall be taken into account Depreciation;

 

    27 

     

    

 

(vi)        to
the extent an adjustment to the adjusted tax basis of any Company asset pursuant to Code Section 734(b) is required, pursuant to
Treasury Regulations Section 1.704-1(b)(2)(iv)(m)(4), to be taken into account in determining Capital Accounts as a result of a
distribution other than in liquidation of a Member’s interest in the Company, the amount of such adjustment to the Capital
Accounts will be treated as an item of gain (if the adjustment increases the basis of the asset) or loss (if the adjustment decreases
such basis) from the disposition of such asset and shall be taken into account for purposes of computing Profits or Losses; and

 

(vii)       any
items that are allocated pursuant to Section 7.2 or 7.4 shall not be taken into account in computing Profits
and Losses, but the amounts of the items of income, gain, loss, or deduction available to be specially allocated pursuant to Section
7.2 or 7.4 will be determined by applying rules analogous to those set forth in clauses (i) through (vi) above.

 

“Regulatory
Allocations” has the meaning for such term set forth in Section 7.4.

 

“Subscription
Agreement” means that certain Subscription Agreement, dated as of the date hereof, by and between the Company and Bryan.

 

“Tax Matters
Member” has the meaning for such term set forth in Section 7.8.

 

“Taxable Year”
means the period (i) commencing on the date hereof or, for any Taxable Year other than the initial Taxable Year, the first day
after the end of the immediately preceding Taxable Year and (ii) ending (A) on the last day of each Taxable Year, (B) on the day
immediately preceding any day on which an adjustment to the Book Value of the Company’s properties pursuant to clauses
(ii)(A), (ii)(B), (ii)(C) or (ii)(E) of the definition of “Book Value” occurs, or (C) immediately
after any day on which an adjustment to the Book Value of the Company’s properties pursuant to clause (ii)(D) of the
definition of “Book Value” occurs.

 

“Treasury
Regulations” means final or temporary regulations promulgated by the U.S. Department of the Treasury under the
Code, as they may be amended from time to time.

 

“Transfer”
has the meaning for such term set forth in Section 2.2.

 

“Unit”
has the meaning set forth in Section 2.1.

 

10.2         Captions,
References. Pronouns, wherever used herein, and of whatever gender, shall include natural persons and corporations and associations
of every kind and character, and the singular shall include the plural wherever and as often as may be appropriate. Article, section,
exhibit and schedule headings are for convenience of reference and shall not affect the construction or interpretation of this
Agreement. Whenever the terms “hereof,” “hereby,” “herein” or words of similar import are used
in this Agreement they shall be construed as referring to this Agreement in its entirety rather than to a particular section or
provision, unless the context specifically indicates to the contrary. Whenever the word “including” is used herein,
it shall be construed to mean including without limitation. Any reference to a particular “Article,” “Section,”
“Exhibit” or “Schedule” shall be construed as referring to the indicated article, section, exhibit or schedule
of this Agreement unless the context indicates to the contrary.

 

    28 

     

    

 

10.3         Strict
Construction. The parties hereto have participated collectively in the
negotiation and drafting of this Agreement; accordingly, if any ambiguity or question of intent or interpretation arises, then
it is the intent of the parties hereto that this Agreement shall be construed as if drafted collectively by the parties hereto,
and it is the intent of the parties hereto that no presumption or burden of proof shall arise favoring or disfavoring any party
hereto by virtue of the authorship of any provisions of this Agreement.

 

[END OF PAGE]

[SIGNATURE PAGE FOLLOWS]

 

    29 

     

    

 

SIGNATURE PAGE TO

AMENDED AND RESTATED
LIMITED LIABILITY COMPANY AGREEMENT OF IBIO CMO LLC

 

IN WITNESS WHEREOF, the
parties hereto have executed this Agreement as of the date first above written.

 

	 	iBio CMO LLC	 
	 	 	 	 
	 	By: 	/s/
    Robert L. Erwin	 
	 	 	Name: 	Robert L. Erwin	 
	 	 	Title:	Manager	 
	 	 	 	 
	 	

                    Bryan Capital Investors LLC
	 
	 	 	 	 
	 	By:
    	/s/
    Tim Sullivan	 
	 	 	Name:  	Tim Sullivan	 
	 	 	Title:	Chief Financial Officer	 
	 	 	 	 
	 	

                    iBio, Inc.
	 
	 	 	 	 
	 	By:  	/s/
    Robert B. Kay	 
	 	 	Name: 	Robert B. Kay	 
	 	 	Title:  	CEO	 

 

    30 

     

    

 

EXHIBIT A

 

SCHEDULE OF MEMBERS

 

	Name and Address of Member	 	Initial Capital Contributions	 	 	Units	 
	 	 	 	 	 	 	 
	iBio, Inc. 
600 Madison Avenue 
Suite 1601, New York, NY Facsimile: 302-356-1173	 	$	35,000,000	 	 	 	70,000,000	 
	Bryan Capital Investors LLC 
124 Allawood Court 
Simpsonville, SC 29681 
Facsimile: 864-252-9316	 	$	15,000,000	 	 	 	30,000,000	 
	TOTAL	 	$	50,000,000	 	 	 	100,000,000	 

 

    A-2Exhibit 10.4

 

Execution Copy

 

License Agreement

 

This License Agreement
(this “Agreement”), dated as of January 13, 2016 (the “Effective Date”), is made by and between
iBio, Inc., a Delaware corporation (“iBio”), and iBio CMO LLC, a Delaware limited liability company (“Licensee”).
Each of iBio and Licensee may be referred to herein as a “Party” or together as the “Parties.”

 

WHEREAS, iBio has developed
and owns or has rights to certain patents and technology for the accelerated discovery and production of improved vaccines, monoclonal
antibodies, therapeutic proteins, and other products derived from green plants utilizing its iBioLaunchTM plant-based platform
technology and other proprietary technologies;

 

WHEREAS, Licensee wishes
to obtain commercial rights to iBio’s patents and technologies for research, process development and scale-up, and manufacturing
of plant-derived products in a manufacturing facility designed for that purpose and in accordance with the terms and conditions
set forth below;

 

NOW, THEREFORE, the Parties
hereby agree as follows:

 

1.            Definitions.         As
used in this Agreement, capitalized terms which are not otherwise defined will have the meaning set forth in Schedule A.

 

2.            License
Grants.

 

2.1           Licenses
by iBio

 

(a)          For
Research, Process Development, and Scale-Up. Subject to the terms and conditions of this Agreement, iBio hereby grants to Licensee
a nonexclusive license in the Territory, with the right to sublicense only as permitted by Section 2.3, to use iBioLaunchTM
Technology and iBio Additional Technology to conduct Process Development, Scale-Up, and R&D activities on Pharmaceutical Products
in the Territory. Additionally, subject to the terms and conditions of this Agreement, iBio hereby grants to Licensee a nonexclusive
license in the Territory, with the right to sublicense only as permitted by Section 2.3, to use the iBio Additional Technology
to conduct Process Development, Scale-Up, and R&D activities on Products in the Territory.

 

(b)          For
Manufacturing. Subject to the terms and conditions of this Agreement, iBio hereby grants to Licensee an exclusive license in
the Territory, with the right of sublicense only as permitted by Section 2.3, to use iBioLaunchTM Technology and iBio Additional
Technology to Manufacture Pharmaceutical Products in the Territory. Additionally, subject to the terms and conditions of this Agreement,
iBio hereby grants to Licensee an exclusive license in the Territory, with the right to sublicense only as permitted by Section
2.3, to use the iBio Additional Technology to Manufacture Products in the Territory.

 

(c)          For
Technology Transfer. Subject to the terms and conditions of this Agreement, iBio hereby grants to Licensee a non-exclusive
license in the Territory to provide Technology Transfer services for, and to grant sublicenses under, the iBioLaunch Technology
and iBio Additional Technology to customers which have been approved in writing by iBio.

 

     

     

    

  

(d)          Retention
of Rights. Except for the licenses granted in Sections 2.1(a), 2.1(b), and 2.1(c), iBio is retaining all other rights in its
intellectual property.

 

2.2           Assignment
by Licensee and Grant-Back Licenses. Subject to the terms and conditions
of this Agreement, Licensee, for itself and on behalf of its Affiliates and subcontractors, and employees, consultants and agents
of any of the foregoing, hereby assigns (and to the extent such assignment can only be made in the future hereby agrees to assign),
to iBio all right, title and interest in and to any Improvement conceived or reduced to practice during the Term of this Agreement,
whether patentable or not (unless already owned by iBio). Licensee will cooperate, and will cause the foregoing Persons to cooperate
with iBio to effectuate and perfect the foregoing ownership, including by promptly executing and recording assignments and other
documents consistent with such ownership. All such Improvements will be deemed to be iBio Additional Technology and subject to
the licenses granted to Licensee by Sections 2.1(a), 2.1(b) and 2.1(c). For clarity, and notwithstanding anything to the contrary
in this Section 2.2, nothing contained herein will preclude Licensee from using its general knowledge, skills and experience, and
any ideas, concepts, Know-How, and techniques that are acquired or used in the course of providing the goods and services to customers
pursuant to this Agreement.

 

2.3           Sublicensing
Rights. The licenses granted in Section 2.1 may not be sublicensed or assigned by Licensee, in full or in part, without the
prior written consent of iBio, which consent will not be unreasonably withheld.

 

2.4           Coordination
of Business Development.

 

(a)          In
order to facilitate the development of business relations for each of iBio and Licensee, the Parties agree to coordinate and otherwise
cooperate with each other’s efforts to obtain customers for Licensee’s Process Development, Scale-Up and Manufacturing
services and licensees for the use of rights to the iBioLaunchTM Technology and iBio Additional Technology retained by iBio
pursuant to this Agreement.

 

(b)          iBio
agrees and understands that the rights granted to Licensee under this Agreement are limited to the use of iBioLaunch Technology
and iBio Additional Technology for Process Development, Scale-Up, R&D, and Manufacturing activities. iBio will work in good
faith to negotiate on commercially reasonable terms and grant to customers of Licensee any such additional license rights as such
customer may need to make use of the goods and services provided by Licensee to such customer. For clarity, iBio agrees that Licensee
may give to its customers the Pharmaceutical Products and/or Products manufactured by Licensee for such customer, and the parties
will work together in good faith to prepare, negotiate, and enter into an appropriate material transfer agreement with such customer
to the extent necessary.

 

3.            License
As Capital Contribution to Licensee

 

The rights granted to
Licensee under this Agreement are being contributed to the capital of Licensee by iBio, without any upfront consideration payable
by Licensee to iBio, but subject to all of the prospective obligations and limitations set forth in this Agreement.

 

     

     

    

  

4.            Payments
and Royalties

 

4.1           Royalties

 

(a)          Royalties
and Rates. Subject to the remainder of this Section 4, Licensee will pay to iBio, within sixty (60) days after the end of each
calendar quarter, a royalty equal to two percent (2%) of the net amount received, taking into account rebates, credits, and other
discounts given to customers, in such calendar quarter by Licensee from the sale of goods or services which use any of the rights
granted to Licensee under Section 2.1 (such gross amounts are referred to as the “Net Receipts”). Goods and
services will be considered “sold” when a sale is recognized in accordance with revenue recognition policies mandated
by GAAP.

 

(b)          Additional
Royalty Provisions. Royalties when owed or paid hereunder will be paid only on amounts actually received by Licensee from customers,
and except as provided in Section 4.3(c), will be non-refundable and non-creditable and not subject to set-off.

 

(c)          No
Double Royalties. For clarity to the extent a payment received by Licensee would be considered both a Net Receipt (pursuant
to Section 4.1(a)) and Financial Consideration (pursuant to Section 4.2), such payment will be deemed a Net Receipt and not Financial
Consideration so that Licensee will not be required to pay more than a two percent (2%) royalty on such payment.

 

4.2           Sublicense
Consideration. Licensee will pay to iBio a royalty equal to two percent (2%) of all Financial Consideration Licensee or any
of its Affiliates receives in connection with any sublicense agreement of the licenses set forth in Section 2.1 in the Territory.

 

4.3           Payment
Terms

 

(a)          Manner
of Payment. All payments to be made by Licensee hereunder will be made in U.S. dollars via check or wire transfer to such bank
account as iBio may designate.

 

(b)          Reports
and Royalty Payments. For as long as royalties are due under Sections 4.1 and 4.2, Licensee will furnish to iBio a written
report, after the end of each calendar quarter, showing the amount of Net Receipts and royalty due, Financial Consideration and
royalty due under Section 4.2, which report will be furnished within sixty (60) days of the end of such calendar quarter for Net
Receipts generated by Licensee and its Affiliates, and within ninety (90) days of the end of such calendar quarter for Financial
Consideration. Royalties for each calendar quarter will be due at the same time as such written reports for the calendar quarter.

 

(c)          Records
and Audits. Licensee will keep adequate books and records of accounting for the purposes of calculating all royalties payable
hereunder and ensuring compliance hereunder. For the four (4) years following the end of the Fiscal Year to which each will pertain,
such books and records of accounting will be kept at Licensee’s principal place of business. At the request of iBio, Licensee
will permit an independent Third Party auditor, subject to Licensee’s prior written consent, at reasonable times and upon
reasonable notice, to examine the books and records maintained pursuant to Section 4.3(b). Such examinations may not (i) be conducted
for any Fiscal Year more than four (4) years after the end of such year, (ii) be conducted more than once in any twelve (12) month
period or (iii) be repeated for any Fiscal Year. Except as provided below, the cost of this examination will be borne by iBio,
unless the audit reveals a variance of more than ten percent (10%) from the reported amounts, in which case the Licensee will bear
the cost of the audit. Unless disputed as described below, if such audit concludes that additional payments were owed or that excess
payments were made during such period, the Licensee will pay the additional royalties or amounts or iBio will reimburse such excess
payments, with interest from the date originally due as provided in Section 4.3(e), within sixty (60) days after the date on which
a written report of such audit is delivered to both Parties. In the event of a dispute regarding such books and records, including
the amount of royalties owed to iBio under this Section 4.3(b), iBio and Licensee will work in good faith to resolve the disagreement.
If the Parties are unable to reach a mutually acceptable resolution of any such dispute within thirty (30) days, such dispute will
be resolved in accordance with Section 9.1(d). The receiving Party will treat all information subject to review under this Section
4.3(b) in accordance with the confidentiality provisions of Section 6 and the Parties will cause any auditor or arbitrator to enter
into a reasonably acceptable confidentiality agreement with the audited Party obligating such firm to retain all such financial
information in confidence pursuant to such confidentiality agreement.

 

     

     

    

  

(d)          Taxes.
Licensee may withhold from payments due to iBio amounts for payment of any withholding tax that is required by law to be paid to
any taxing authority with respect to such payments. Licensee will provide iBio all relevant documents and correspondence, and will
also provide to iBio any other cooperation or assistance on a reasonable basis as may be necessary to enable iBio to claim exemption
from such withholding taxes and to receive a refund of such withholding tax or claim a foreign tax credit. Licensee will give proper
evidence from time to time as to the payment of any such tax.

 

(e)          Interest
Due. If any payment due to either Party under this Agreement is overdue (and is not subject to a good faith dispute), then
such paying Party will pay interest thereon (before and after any judgment) at an annual rate (but with interest accruing on a
daily basis) of the lesser of two percent (2%) above the prime rate as reported in The Wall Street Journal, Eastern Edition,
and the maximum rate permitted by applicable law, such interest to run from the date upon which payment of such sum became due
until payment thereof in full together with such interest.

 

(f)          Royalty
Term. Licensee’s obligation to pay royalties under Sections 4.1 and 4.2 will continue until expiration of this Agreement.

 

5.            Improvement
Patent Prosecution and Maintenance.

 

5.1           Prosecution
and Maintenance.

 

(a)          Inventorship
determination for all Improvement Patents worldwide will be made in accordance with applicable United States patent laws.

 

(b)          iBio
will have the sole financial responsibility for the costs of Prosecution and Maintenance of the Improvement Patents and will have
the sole right to determine the scope of such Prosecution and Maintenance activities.

 

(c)          In
the event that iBio desires to abandon or cease Prosecution or Maintenance of any Improvement Patent, iBio shall provide reasonable
prior written notice to Licensee of such intention to abandon (which notice shall, to the extent possible, be given no later than
ninety (90) calendar days prior to the next deadline for any action that must be taken with respect to any such Improvement Patent).
In such case, at Licensee’s sole discretion, upon written notice from Licensee, Licensee may elect to continue Prosecution
and Maintenance of any such Improvement Patent at its own expense, and iBio shall cooperate in a timely manner to allow Licensee
to continue Prosecution and Maintenance of any such Improvement Patent. Any Improvement Patent abandoned by iBio will be promptly
assigned to Licensee, who will own all right, title and interest in and to such abandoned Improvement Patent.

 

     

     

    

  

5.2           Cooperation.
Licensee will, at iBio’s sole cost and expense, reasonably cooperate with iBio in the Prosecution and Maintenance of
the Improvement Patents. Such cooperation includes promptly executing all documents, or requiring inventors, subcontractors, employees
and consultants and agents of Licensee and its Affiliates and Sublicensees to execute all documents, as reasonable and appropriate
so as to enable the Prosecution and Maintenance of any such Improvement Patents in any country.

 

6.            Confidentiality.

 

6.1           Confidential
Information.

 

(a)          Confidential
Information. Each Party (“Disclosing Party”) may disclose to the other Party (“Receiving Party”),
and Receiving Party may acquire during the course and conduct of activities under this Agreement, certain proprietary or confidential
information of Disclosing Party in connection with this Agreement. The term “Confidential Information” will mean (i)
all Materials and (ii) all ideas and information of any kind, whether in written, oral, graphical, machine-readable or other form,
whether or not marked as confidential or proprietary, which are transferred, disclosed or made available by Disclosing Party or
at the request of Receiving Party, including any of the foregoing of Third Parties. Without limiting the foregoing, iBioLaunchTM
Technology and iBio Additional Technology will be considered Confidential Information of iBio.

 

(b)          Restrictions.
During the Term and for ten (10) years thereafter, Receiving Party will keep all Disclosing Party’s Confidential Information
in confidence with the same degree of care with which Receiving Party holds its own confidential information. Receiving Party will
not use Disclosing Party’s Confidential Information except for in connection with the performance of its obligations and
exercise of its rights under this Agreement. Receiving Party has the right to disclose Disclosing Party’s Confidential Information
without Disclosing Party’s prior written consent, to the extent and only to the extent reasonably necessary, to Receiving
Party’s Affiliates and their employees, subcontractors, consultants or agents who have a need to know such Confidential Information
in order to perform its obligations and exercise its rights under this Agreement and who are bound by obligations of non-use and
non-disclosure at least as restrictive as this Section 6.1(b). Receiving Party will use diligent efforts to cause those Persons
to comply with the restrictions on use and disclosure in this Section 6.1(b). Receiving Party assumes responsibility for those
entities and persons maintaining Disclosing Party’s Confidential Information in confidence and using same only for the purposes
described herein.

 

(c)          Exceptions.
Receiving Party’s obligation of nondisclosure and the limitations upon the right to use the Disclosing Party’s Confidential
Information will not apply to the extent that Receiving Party can demonstrate that the Disclosing Party’s Confidential Information:
(i) was known to Receiving Party, its Affiliates, its Sublicensees, or any of their and their employees, subcontractors, consultants
or agents prior to the time of disclosure; (ii) is or becomes public knowledge through no fault or omission of Receiving Party
or any of its Affiliates; (iii) is obtained by Receiving Party, its Affiliates, its Sublicensees, or any of their and their employees,
subcontractors, consultants or agents from a Third Party under no obligation of confidentiality to Disclosing Party; or (iv) has
been independently developed by employees, subcontractors, consultants or agents of Receiving Party or any of its Affiliates or
Sublicensees without the aid, application or use of Disclosing Party’s Confidential Information, as evidenced by contemporaneous
written records. Notwithstanding the foregoing, the exceptions set forth in Sections 6.1(c)(i), (iii), or (iv) shall not apply
to excuse the disclosure of Confidential Information by any Person who is an employee and/or representative of both iBio and Licensee.

 

     

     

    

  

(d)          Permitted
Disclosures. Receiving Party may disclose Disclosing Party’s Confidential Information to the extent (and only to the
extent) such disclosure is reasonably necessary in the following instances:

 

(i)          in
order to comply with applicable law (including any securities law or regulation or the rules of a securities exchange) or with
a legal or administrative proceeding;

 

(ii)         in
connection with prosecuting or defending litigation, or obtaining Regulatory Approvals and other regulatory filings and communications,
and filing, prosecuting and enforcing Patents in connection with Receiving Party’s rights and obligations pursuant to this
Agreement; and

 

(iii)        in
connection with exercising its rights hereunder, to its Affiliates; potential and future collaborators (including Sublicensees
where Licensee is the Receiving Party); permitted acquirers or assignees; and investment bankers, investors and lenders, and its
or their counsel;

 

provided that (1) with
respect to Sections 6.1(d)(i) or 6.1(d)(ii), where reasonably possible, Receiving Party will notify Disclosing Party of Receiving
Party’s intent to make any disclosure pursuant thereto sufficiently prior to making such disclosure so as to allow Disclosing
Party adequate time to take whatever action it may deem appropriate to protect the confidentiality of the information to be disclosed,
and (2) with respect to Section 6.1(d)(iii), each of those named people and entities are required to comply with the restrictions
on use and disclosure in Section 6.1(b) (other than investment bankers, investors, lenders and counsel, which must be bound prior
to disclosure by commercially reasonable obligations of confidentiality).

 

7.            Warranties;
Limitations of Liability; Indemnification.

 

7.1           Representations
and Warranties. Each Party represents and warrants to the other as of the Effective Date that it has the legal right and power
to enter into this Agreement, to extend the rights and licenses granted or to be granted to the other in this Agreement, and to
fully perform its obligations hereunder.

 

7.2           Additional
Representations and Warranties of iBio. iBio represents and warrants to Licensee that, as of the Effective Date:

 

(a)          iBio
controls the Patents listed on Schedule B and is entitled to grant the licenses specified herein. iBio has not caused any Patent
included on such Exhibit to be subject to any liens or encumbrances.

 

(b)          iBio
has not granted to any Third Party any rights or licenses under such Patents or that would conflict with the licenses granted to
Licensee hereunder.

 

     

     

    

  

(c)          To
the best of its knowledge, after appropriate inquires have been made by iBio, none of the information, data, or materials provided
to Licensee or its representatives or counsel prior to the Effective Date by or on behalf of iBio related to the iBioLaunchTM
Technology and the iBio Additional Technology is inaccurate in any material respect, and there is no data or information that iBio
considers material that is within iBio’s or its Affiliate’s possession that causes, due to lack of disclosure, specific
data or other information disclosed by iBio to Licensee or its representatives or counsel relating to the iBioLaunchTM Technology
and the iBio Additional Technology to be misleading in any respect.

 

(d)          To
the best of its knowledge, after appropriate inquires have been made by iBio, the research, development, manufacture and use of
the iBioLaunchTM Technology and the iBio Additional Technology in the United States as of the Effective Date will not infringe
or misappropriate any Patent or other intellectual property right owned or Controlled by a Third Party.

 

7.3           Additional
Covenants of iBio. During the Term, iBio will use diligent and commercially reasonable efforts to maintain the confidentiality
of iBio’s Confidential Information, including its non-public Know-How and prevent disclosure of such Confidential Information
in a manner that could reasonably damage the business interests of iBio and/or Licensee.

 

7.4           Disclaimers.         Without
limiting the respective rights and obligations of the Parties expressly set forth herein, iBio specifically disclaims any guarantee
that any Pharmaceutical Products or Products will be successful, in whole or in part. The failure of the Licensee to successfully
produce Pharmaceutical Products or Products or to develop a cost effective and regulatory compliant manufacturing process for
such products will not constitute a breach of any representation or warranty under this Agreement. EXCEPT AS OTHERWISE EXPRESSLY
PROVIDED IN THIS AGREEMENT, NEITHER PARTY MAKES ANY REPRESENTATIONS AND EXTENDS NO WARRANTY OF ANY KIND, EITHER EXPRESS OR IMPLIED,
WITH RESPECT TO ANY PATENTS, TECHNOLOGY, KNOW- HOW, MATERIALS, FACILITIES, PHARMACEUTICAL PRODUCTS, OR PRODUCTS, INCLUDING WARRANTIES
OF TITLE, QUALITY, MERCHANTABILITY, FITNESS FOR A PARTICULAR USE OR PURPOSE, AND PERFORMANCE.

 

7.5           No
Consequential Damages.         NOTWITHSTANDING ANYTHING IN THIS AGREEMENT OR
OTHERWISE, NEITHER PARTY WILL BE LIABLE TO THE OTHER OR ANY THIRD PARTY WITH RESPECT TO ANY SUBJECT MATTER OF THIS AGREEMENT FOR
ANY INDIRECT, PUNITIVE, SPECIAL OR CONSEQUENTIAL DAMAGES, EVEN IF SUCH PARTY HAS BEEN INFORMED OR SHOULD HAVE KNOWN OF THE POSSIBILITY
OF SUCH DAMAGES; PROVIDED THAT THIS SECTION 7.5 WILLNOTAPPLYTOTHEPARTIES’INDEMNIFICATIONRIGHTSAND
OBLIGATIONS UNDER SECTION 7.7.

 

7.6           Performance
by Others. The Parties recognize that each Party may perform some or all of its obligations under this Agreement through
Affiliates and permitted subcontractors provided, however, that each Party will remain responsible and liable for the performance
by its Affiliates and permitted subcontractors and will cause its Affiliates and permitted subcontractors to comply with the provisions
of this Agreement in connection therewith.

 

     

     

    

  

7.7           Indemnification.

 

(a)          Indemnification
of iBio. Licensee will indemnify iBio, its Affiliates and their respective directors, officers, employees, and agents, and
their respective successors, heirs and assigns (collectively, ”iBio Indemnitees”), and defend and save each
of them harmless, from and against any and all losses, damages, liabilities, costs and expenses (including reasonable attorneys’
fees and expenses) (collectively, “Losses”) in connection with any and all suits, investigations, claims or
demands of Third Parties (collectively, “Third Party Claims”) arising from or occurring as a result of: (i)
the material breach by Licensee of any term of this Agreement; or (ii) any gross negligence or willful misconduct on the part of
Licensee in performing its obligations under this Agreement, except in each case for those Losses as to which iBio has an obligation
to indemnify Licensee pursuant to Section 7.7(b), as to which Losses each Party will indemnify the other to the extent of their
respective liability; provided, however, that Licensee will not be obligated to indemnify iBio Indemnitees for any Losses to the
extent that such Losses arise as a result of gross negligence or willful misconduct on the part of an iBio Indemnitee.

 

(b)          Indemnification
of Licensee. iBio will indemnify Licensee, its Affiliates and their respective directors, officers, employees and agents,
and their respective successors, heirs and assigns (collectively, ”Licensee Indemnitees”), and defend and save
each of them harmless, from and against any and all Losses in connection with any and all Third Party Claims arising from or occurring
as a result of: (i) the material breach by iBio of any term of this Agreement; (ii) any gross negligence or willful misconduct
on the part of iBio in performing its obligations under this Agreement; (iii) the use of any iBioLaunchTM Technology or iBio
Additional Technology as contemplated under this Agreement, including any such Third Party Claims alleging infringement or misappropriation
of Third Party intellectual property rights; or (iv) any dispute between iBio and a customer of Licensee, except in each case
for those Losses for which Licensee has an obligation to indemnify iBio pursuant to Section 7.7(a), as to which Losses each Party
will indemnify the other to the extent of their respective liability for the Losses; provided, however, that iBio will not be
obligated to indemnify Licensee Indemnitees for any Losses to the extent that such Losses arise as a result of gross negligence
or willful misconduct on the part of a Licensee Indemnitee.

 

(c)          Notice
of Claim. All indemnification claims provided for in Section 7.7(a) and 7.7(b) will be made solely by such Party to this Agreement
(the ”Indemnified Party”). The Indemnified Party will promptly notify the indemnifying Party (an ”Indemnification
Claim Notice”) of any Losses or the discovery of any fact upon which the Indemnified Party intends to base a request
for indemnification under Section 7.7(a) or 7.7(b), but in no event will the indemnifying Party be liable for any Losses that result
from any delay in providing such notice. Each Indemnification Claim Notice must contain a description of the claim and the nature
and estimated amount of such Loss (to the extent that the nature and amount of such Loss is known at such time). The Indemnified
Party will furnish promptly to the indemnifying Party copies of all papers and official documents received in respect of any Losses
and Third Party Claims.

 

     

     

    

  

(d)          Defense,
Settlement, Cooperation and Expenses.

 

(i)          Control
of Defense. At its option, the indemnifying Party may assume the defense of any Third Party Claim by giving written notice
to the Indemnified Party within thirty (30) days after the indemnifying Party’s receipt of an Indemnification Claim Notice.
The assumption of the defense of a Third Party Claim by the indemnifying Party will not be construed as an acknowledgment that
the indemnifying Party is liable to indemnify the Indemnified Party in respect of the Third Party Claim, nor will it constitute
a waiver by the indemnifying Party of any defenses it may assert against the Indemnified Party’s claim for indemnification.
Upon assuming the defense of a Third Party Claim, the indemnifying Party may appoint as lead counsel in the defense of the Third
Party Claim any legal counsel selected by the indemnifying Party (the indemnifying Party will consult with the Indemnified Party
with respect to a possible conflict of interest of such counsel retained by the indemnifying Party). In the event the indemnifying
Party assumes the defense of a Third Party Claim, the Indemnified Party will immediately deliver to the indemnifying Party all
original notices and documents (including court papers) received by the Indemnified Party in connection with the Third Party Claim.
Should the indemnifying Party assume the defense of a Third Party Claim, except as provided in Section 7.7(d)(ii), the indemnifying
Party will not be liable to the Indemnified Party for any legal costs or expenses subsequently incurred by such Indemnified Party
in connection with the analysis, defense or settlement of the Third Party Claim. In the event that it is ultimately determined
that the indemnifying Party is not obligated to indemnify, defend or hold harmless the Indemnified Party from and against the Third
Party Claim, the Indemnified Party will reimburse the indemnifying Party for any and all costs and expenses (including attorneys’
fees and costs of suit) and any Third Party Claims incurred by the indemnifying Party in its defense of the Third Party Claim.

 

(ii)         Right
to Participate in Defense. Without limiting Section 7.7(d)(i), any Indemnified Party will be entitled to participate in, but
not control, the defense of such Third Party Claim and to employ counsel of its choice for such purpose; provided, however, that
such employment will be at the Indemnified Party’s own cost and expense unless (i) the employment thereof has been specifically
authorized by the indemnifying Party in writing, (ii) the indemnifying Party has failed to assume the defense and employ counsel
in accordance with Section 7.7(d)(i) (in which case the Indemnified Party will control the defense) or (iii) the interests of the
Indemnified Party and the indemnifying Party with respect to such Third Party Claim are sufficiently adverse to prohibit the representation
by the same counsel of both Parties under applicable law, ethical rules or equitable principles in which case the indemnifying
Party will assume one hundred percent (100%) of any such costs and expenses of counsel for the Indemnified Party.

 

(iii)        Settlement.
With respect to any Third Party Claims that relate solely to the payment of money damages in connection with a Third Party Claim
and that will not result in the Indemnified Party’s becoming subject to injunctive or other relief or otherwise adversely
affecting the business of the Indemnified Party in any manner, and as to which the indemnifying Party will have acknowledged in
writing the obligation to indemnify the Indemnified Party hereunder, the indemnifying Party will have the sole right to consent
to the entry of any judgment, enter into any settlement or otherwise dispose of such Loss, on such terms as the indemnifying Party,
in its sole discretion, will deem appropriate. With respect to all other Losses in connection with Third Party Claims, where the
indemnifying Party has assumed the defense of the Third Party Claim in accordance with Section 7.7(d)(i), the indemnifying Party
will have authority to consent to the entry of any judgment, enter into any settlement or otherwise dispose of such Loss provided
it obtains the prior written consent of the Indemnified Party (which consent will not be unreasonably withheld). The indemnifying
Party will not be liable for any settlement or other disposition of a Loss by an Indemnified Party that is reached without the
written consent of the indemnifying Party. Regardless of whether the indemnifying Party chooses to defend or prosecute any Third
Party Claim, no Indemnified Party will admit any liability with respect to or settle, compromise or discharge, any Third Party
Claim without the prior written consent of the indemnifying Party, such consent not to be unreasonably withheld.

 

     

     

    

  

(iv)        Cooperation.
Regardless of whether the indemnifying Party chooses to defend or prosecute any Third Party Claim, the Indemnified Party will,
and will cause each other Indemnified Party to, cooperate in the defense or prosecution thereof and will furnish such records,
information and testimony, provide such witnesses and attend such conferences, discovery proceedings, hearings, trials and appeals
as may be reasonably requested in connection therewith. Such cooperation will include access during normal business hours afforded
to indemnifying Party to, and reasonable retention by the Indemnified Party of, records and information that are reasonably relevant
to such Third Party Claim, and making Indemnified Parties and other employees and agents available on a mutually convenient basis
to provide additional information and explanation of any material provided hereunder, and the indemnifying Party will reimburse
the Indemnified Party for all its reasonable out-of-pocket costs and expenses in connection therewith.

 

(v)         Costs
and Expenses. Except as provided above in this Section 7.7(d), the costs and expenses, including attorneys’ fees and
expenses, incurred by the Indemnified Party in connection with any claim will be reimbursed on a calendar quarter basis by the
indemnifying Party, without prejudice to the indemnifying Party’s right to contest the Indemnified Party’s right to
indemnification and subject to refund in the event the indemnifying Party is ultimately held not to be obligated to indemnify the
Indemnified Party.

 

7.8           Insurance.
Each Party will maintain at its sole cost and expense, an adequate liability insurance or self-insurance program (including product
liability insurance) to protect against potential liabilities and risk arising out of activities to be performed under this Agreement
and any agreement related hereto and upon such terms (including coverages, deductible limits and self-insured retentions) as are
customary in the U.S. pharmaceutical industry for the activities to be conducted by such Party under this Agreement. Subject to
the preceding sentence, such liability insurance or self-insurance program will insure against all types of liability, including
personal injury, physical injury or property damage arising out of the manufacture, sale, use, distribution or marketing of Pharmaceutical
Products or Products. The coverage limits set forth herein will not create any limitation on a Party’s liability to the other
under this Agreement.

 

     

     

    

  

8.            Term
and Termination.

 

8.1           Term.
This Agreement will commence as of the Effective Date and, unless sooner terminated in accordance with the terms hereof or by mutual
written consent, will continue until the later of (i) the expiration of the term of the Licensee’s Sublease or (ii) there
are no more payments owed to iBio under Sections 4.1 or 4.2 (the “Term”).

 

8.2           Termination
by iBio. iBio will have the right to terminate this Agreement in full upon delivery of written notice to Licensee in
the event of any material breach by Licensee of any terms and conditions of this Agreement, provided that such termination will
not be effective if such breach has been cured within ninety (90) days after written notice thereof is given by iBio to Licensee
specifying the nature of the alleged breach (or, if such default cannot be cured within such ninety (90) day period, within one
hundred and eighty (180) days after such notice if Licensee commences actions to cure such default within such 90-day period and
thereafter diligently continues such actions, but fails to cure the default by the end of such 180-days); provided, however, that
to the extent such material breach involves the failure to make a payment when due, such breach must be cured within thirty (30)
days after written notice thereof is given by iBio to Licensee. Notwithstanding the foregoing, in no event may iBio terminate this
Agreement under this Section 82(a) if Licensee’s material breach is a result of any act or failure to act of iBio, any Affiliate,
or any of their employees, agents, contractors, directors or officers.

 

8.3           Termination
by Licensee. Licensee will have the right to terminate this Agreement in full upon delivery of written notice to iBio in the
event of any material breach by iBio of any terms and conditions of this Agreement, provided that such termination will not be
effective if such breach has been cured within ninety (90) days after written notice thereof is given by Licensee to iBio specifying
the nature of the alleged breach (or, if such default cannot be cured within such ninety (90) day period, within one hundred and
eighty (180) days after such notice if iBio commences actions to cure such default within such 90-day period and thereafter diligently
continues such actions, but fails to cure the default by the end of such 180-days); provided, however, that to the extent such
material breach involves the failure to make a payment when due, such breach must be cured within thirty (30) days after written
notice thereof is given by Licensee to iBio.

 

8.4           Termination
Upon Bankruptcy.

 

(a)          Termination
Right. Either Party may terminate this Agreement if, at any time, the other Party will file in any court or agency pursuant
to any statute or regulation of any state, country or jurisdiction, a petition in bankruptcy or insolvency or for reorganization
or for an arrangement or for the appointment of a receiver or trustee of that Party or of its assets, or if the other Party proposes
a written agreement of composition or extension of its debts, or if the other Party will be served with an involuntary petition
against it, filed in any insolvency proceeding, and such petition will not be dismissed within sixty (60) days after the filing
thereof, or if the other Party will propose or be a Party to any dissolution or liquidation, or if the other Party will make an
assignment for the benefit of its creditors.

 

(b)          Consequences
of Bankruptcy. All rights and licenses granted under or pursuant to this Agreement by Licensee or iBio or their Affiliates
are, and will otherwise be deemed to be, for purposes of Section 365(n) of the U.S. Bankruptcy Code, licenses of right to “intellectual
property” as defined under Section 101 of the U.S. Bankruptcy Code. The Parties agree that the Parties and their respective
Affiliates, and Sublicensees, as licensees of such rights under this Agreement, will retain and may fully exercise all of their
rights and elections under the U.S. Bankruptcy Code and any foreign counterparts thereto.

 

     

     

    

  

8.5           Effects
of Termination. Upon termination by iBio under Section 8.2, all rights and licenses granted by iBio to Licensee in Section
2.1 will terminate, and Licensee and its Affiliates and Sublicensees will cease all use of iBioLaunchTM Technology, iBio Additional
Technology, Materials, and Patents, and will cease all Manufacturing. Upon expiration of this Agreement under Section 8.1, or termination
by Licensee under Section 8.3 or 8.4, all rights and licenses granted by iBio to Licensee in Section 2.1 will become fully paid-up
and perpetual.

 

8.6           Survival. In
addition to the termination consequences set forth in Section 8.5, the following provisions will survive termination or expiration
of this Agreement, as well as any other provision which by its terms or by the context thereof, is intended to survive such termination:
Section 4.3, 5, 6, 7.4, 7.5, 7.6, 7.7, 8 and 9. Termination or expiration of this Agreement will not relieve the Parties of any
liability or obligation which accrued hereunder prior to the effective date of such termination or expiration nor preclude either
Party from pursuing all rights and remedies it may have hereunder or at law or in equity with respect to any breach of this Agreement
nor prejudice either Party’s right to obtain performance of any obligation. All other rights and obligations will terminate
upon expiration of this Agreement.

 

9.            General
Provisions.

 

9.1           Governing
Law; Dispute Resolution.

 

(a)          This
Agreement shall be governed and construed in accordance with the laws of the State of New York, U.S.A., without regard to conflicts
of laws provisions.

 

(b)          In
the event of any dispute, controversy, or claim arising out of, relating to, or in connection with this Agreement, or the breach,
termination, or validity thereof, between the Parties, the Parties will first attempt in good faith to resolve such dispute by
negotiation and consultation between themselves. In the event that such dispute is not resolved on an informal basis within twenty
(20) days, any Party may, by written notice to the other, have such dispute referred to the iBio CEO and the Licensee CEO or in
either case his or her designee (who will be a senior executive), who will attempt in good faith to resolve such dispute by negotiation
and consultation for a thirty (30) day period following receipt of such written notice.

 

(c)          Unless
Section 9.1(b) is applicable, in the event the Parties are not able to resolve such dispute through mediation, either Party may
at any time after such 20-day period submit such dispute to be finally settled by arbitration administered by the American Arbitration
Association (“AAA”), including the AAA’s Procedures for Large, Complex Commercial Disputes, in effect
at the time of the arbitration, except as they may be modified herein or by mutual agreement of the Parties. The seat of the arbitration
shall be New York, New York, and it shall be conducted in the English language. The arbitration and this clause shall be governed
by Title 9 (Arbitration) of the United States Code.

 

(d)          The
arbitration shall be conducted by three arbitrators. The claimant shall appoint an arbitrator in its request for arbitration. The
respondent shall appoint an arbitrator within 20 days of the receipt of the request for arbitration. The two arbitrators shall
appoint a third arbitrator, who shall act as chair of the tribunal, within 20 days after the appointment of the second arbitrator.
If any of the three arbitrators is not appointed within the time prescribed above, then the AAA shall appoint that arbitrator from
its National Panel of Securities Arbitrators or its Large, Complex Commercial Case Panel, not including any such members affiliated
with the securities industry. The chair of the tribunal shall be a citizen of the United States.

 

     

     

    

  

(e)          In
addition to the authority conferred on the arbitration tribunal by the Rules, the arbitration tribunal shall have the authority
to order such production of documents, generally consistent with the discovery permitted under the Federal Rules of Civil Procedure,
as may reasonably be requested by any party or by the tribunal itself. In addition, any party may request a reasonable number of
depositions of Party witnesses.

 

(f)          The
Parties agree that the arbitration shall be kept confidential and that the existence of the proceeding and any element of it (including
but not limited to any pleadings, briefs or other documents submitted or exchanged, any testimony or other oral submissions, and
any awards) shall not be disclosed beyond the tribunal, the AAA, the parties, their counsel, accountants and auditors, insurers
and re-insurers, and any Person necessary to the conduct of the proceeding. The confidentiality obligations shall not apply (i)
if disclosure is required by law, or in judicial or administrative proceedings, or (ii) as far as disclosure is necessary to enforce
the rights arising out of the award.

 

(g)          The
arbitration award shall be final and binding on the parties. Judgment upon the award may be entered by any court having jurisdiction
thereof or having jurisdiction over the relevant Party or its assets.

 

(h)          In
order to facilitate the comprehensive resolution of related disputes, and upon request of any Party to the arbitration proceeding,
the arbitration tribunal may consolidate the arbitration proceeding with any other arbitration proceeding involving any of the
Parties hereto relating to this Agreement. The arbitration tribunal shall not consolidate such arbitrations unless it determines
that (i) there are issues of fact or law common to the related proceedings so that a consolidated proceeding would be more efficient
than separate proceedings, and (ii) no Party would be prejudiced as a result of such consolidation through undue delay or otherwise.

 

9.2           Remedies
Cumulative; Specific Performance. The rights and remedies of the Parties hereto shall be cumulative (and not alternative).
The Parties to this Agreement agree that, in the event of any breach or threatened breach by either Party to this Agreement of
any covenant, obligation or other provision set forth in this Agreement, for the benefit of the other Party to this Agreement:
(a) such other Party shall be entitled (in addition to any other remedy that may be available to it) to: (i) a decree or order
of specific performance or mandamus to enforce the observance and performance of such covenant, obligation or other provision;
and (ii) an injunction restraining such breach or threatened breach; and (b) such other Party shall not be required to provide
any bond or other security in connection with any such decree, order or injunction or in connection with any related action or
legal proceeding.

 

9.3           Relationship
of Parties. Nothing in this Agreement is intended or will be deemed to constitute a partnership, agency, employer-employee
or joint venture relationship between the Parties. No Party will incur any debts or make any commitments for the other, except
to the extent, if at all, specifically provided therein. There are no express or implied third party beneficiaries hereunder (except
for iBio Indemnitees and Licensee Indemnitees for purposes of Section 7.7).

 

     

     

    

  

9.4           Compliance
with Law. Each Party will perform or cause to be performed any and all of its obligations or the exercise of any and all of
its rights hereunder in good scientific manner and in compliance with all applicable law.

 

9.5           Counterparts;
Facsimiles.         This Agreement may be executed in one or more counterparts,
each of which will be deemed an original, and all of which together will be deemed to be one and the same instrument. Facsimile
or PDF execution and delivery of this Agreement by either Party will constitute a legal, valid and binding execution and delivery
of this Agreement by such Party

 

9.6           Headings. All
headings in this Agreement are for convenience only and will not affect the meaning of any provision hereof.

 

9.7           Waiver
of Rule of Construction. Each Party has had the opportunity to consult with counsel in connection with the review, drafting
and negotiation of this Agreement. Accordingly, the rule of construction that any ambiguity in this Agreement will be construed
against the drafting party will not apply.

 

9.8           Interpretation.
Whenever any provision of this Agreement uses the term “including” (or “includes”), such term will
be deemed to mean “including without limitation” (or ”includes without limitations”). “Herein,”
“hereby,” “hereunder,” “hereof” and other equivalent words refer to this Agreement as an entirety
and not solely to the particular portion of this Agreement in which any such word is used. All definitions set forth herein will
be deemed applicable whether the words defined are used herein in the singular or the plural. Unless otherwise provided, all references
to Sections and Exhibits in this Agreement are to Sections and Exhibits of this Agreement. References to any Sections include Sections
and subsections that are part of the related Section (e.g., a section numbered “Section 2.1” would be part of
“Section 2”, and references to “Section 2.1” would also refer to material contained in the subsection described
as “Section 2.1(a)”).

 

9.9           Binding
Effect. This Agreement will inure to the benefit of and be binding upon the Parties, their Affiliates, and their respective
lawful successors and assigns.

 

9.10         Assignment.
This Agreement may not be assigned by either Party, nor may either Party delegate its obligations or otherwise transfer licenses
or other rights created by this Agreement, except as expressly permitted hereunder or otherwise without the prior written consent
of the other Party, which consent will not be unreasonably withheld; provided that

(i) Licensee may assign
this Agreement to an Affiliate or to its successor in connection with the merger, consolidation, or sale of all or substantially
all of its assets or that portion of its business pertaining to the subject matter of this Agreement, and (ii) iBio may assign
this Agreement to an Affiliate or to its successor in connection with the merger, consolidation, or sale of all or substantially
all of its assets or that portion of its business pertaining to the subject matter of this Agreement.

 

9.11         Notices.  All
notices, requests, demands and other communications required or permitted to be given pursuant to this Agreement will be in writing
and will be deemed to have been duly given upon the date of receipt if delivered by hand, recognized international overnight courier,
confirmed facsimile transmission, or registered or certified mail, return receipt requested, postage prepaid to the following
addresses or facsimile numbers:

 

     

     

    

  

	If to iBio:	iBio, Inc.
	 	600 Madison Ave., Suite 1600

 New York, NY USA 10022-1737
	 	Attention:  Chief Executive Officer

 Facsimile:  (302) 356-1173
	 	 
	With a copy to:	Willkie Farr & Gallagher LLP
	 	787 Seventh Avenue

 New York, NY 10019
	 	Attention:  William
Gump

Facsimile:  (212) 728-8111

	 	 
	If to Licensee:	iBio CMO LLC
	 	8800 Health Science Center Parkway

 Bryan, Texas
	 	Attention:  Chief Executive Officer

 Facsimile:  (979) 822-2623
	 	 
	With a copy to:	BoyarMiller
	 	2925 Richmond Avenue, 14th Floor

    Houston, Texas
	 	Attention: Cassie Stinson

 Facsimile:  (713) 552-1758

 

Either Party may change
its designated address and facsimile number by notice to the other Party in the manner provided in this Section 9.11.

 

9.12         Amendment
and Waiver. This Agreement may be amended, supplemented, or otherwise
modified only by means of a written instrument signed by both Parties; provided that any unilateral undertaking or waiver made
by one Party in favor of the other will be enforceable if undertaken in a writing signed by the Party to be charged with the undertaking
or waiver. Any waiver of any rights or failure to act in a specific instance will relate only to such instance and will not be
construed as an agreement to waive any rights or fail to act in any other instance, whether or not similar.

 

9.13         Severability.
In the event that any provision of this Agreement will, for any reason, be held to be invalid or unenforceable in any respect,
such invalidity or unenforceability will not affect any other provision hereof, and the Parties will negotiate in good faith to
modify this Agreement to preserve (to the extent possible) their original intent.

 

9.14         Entire
Agreement. This Agreement is the sole agreement with respect to the subject matter and supersedes all other agreements and
understandings between the Parties with respect to same.

 

9.15         Force
Majeure. Neither Licensee nor iBio will be liable for failure of or delay in performing obligations set forth in this Agreement
(other than any obligation to pay monies when due), and neither will be deemed in breach of such obligations, if such failure
or delay is due to natural disasters or any causes reasonably beyond the control of Licensee or iBio; provided that the Party
affected will promptly notify the other of the force majeure condition and will exert reasonable efforts to eliminate, cure or
overcome any such causes and to resume performance of its obligations as soon as possible.

 

     

     

    

  

IN WITNESS
WHEREOF, the Parties have executed
this Agreement as of
the Effective Date.

 

	iBio Inc.	 
	 	 
	By:	/s/ Robert B. Kay	 
	 	 	 
	Name:	Robert B. Kay	 
	 	 	 
	Title:	CEO	 
	 	 	 
	iBio CMO, LLC	 
	 	 	 
	By:	/s/ Robert L. Erwin	 
	 	 	 
	Name:	Robert L. Erwin	 
	 	 	 
	Title:	Manager	 

 

     

     

    

  

Schedule A

 

Definitions

 

		1.1	“Affiliate” of a person or entity will mean any other entity which (directly
or indirectly) is controlled by, controls or is under common control with such person or entity. For the purposes of this definition,
the term “control” (including, with correlative meanings, the terms ”controlled by” and ”under common
control with”) as used with respect to an entity will mean (i) in the case of a corporate entity, direct or indirect ownership
of voting securities entitled to cast more than fifty percent (50%) of the votes in the election of directors or (ii) in the case
of a non-corporate entity, direct or indirect ownership of more than fifty percent (50%) of the equity interests with the power
to direct the management and policies of such entity. For purposes of this Agreement, iBio is not an Affiliate of Licensee, and
Licensee is not an Affiliate of iBio.

 

		1.2	“Calendar Year” will mean each successive period of twelve (12) calendar months
commencing on January 1 and ending on December 31.

 

		1.3	“Control” or “Controlled” will mean, with respect to any
Know-How, Material, Patent, or other intellectual property right, the possession (whether by ownership or license, other than by
a license granted pursuant to this Agreement) by a Party or its Affiliates of the ability to grant to the other Party a license
or access as provided herein to such Know- How, Material, Patent or other intellectual property right, without violating the terms
of any agreement or other arrangement with any Third Party.

 

		1.4	“Covered” will mean with respect to a product and a Patent, that, but for a
license granted to a Person under a Valid Claim included in such Patent, such Person’s manufacture, use, sale, import, marketing,
offer for sale or commercialization of the product would infringe such Valid Claim or in the case of a Patent that is a patent
application, would infringe a Valid Claim in such patent application if it were to issue as a patent.

 

		1.5	“Financial Consideration” will mean license fees, signing fees, option fees,
milestone payments and any other monetary consideration paid to, or otherwise received by, Licensee or any of its Affiliates in
consideration for the establishment of a Sublicensee relationship (and without reduction for any additional Patents or Know-How
or other intellectual property rights granted or commitments made in connection therewith), but does not include payments received
to purchase securities of Licensee at fair market value, provided that any premium paid over fair market value will be treated
as “Financial Consideration” hereunder.

 

		1.6	“Fiscal Year” will mean each successive period of twelve (12) calendar months
commencing on July 1 and ending on June 30.

 

     

     

    

 

		1.7	“GAAP” will mean U.S. generally accepted accounting principles, consistently
applied.

 

		1.8	“iBioLaunchTM Technology” will mean all Patents and Trademarks listed in
Schedule B and such other Patents, Trademarks, Materials and Know-How as may be identified by iBio from time-to-time in writing
to Licensee and described as falling within the iBioLaunchTM Technology, which are owned (in whole or in part), in-licensed
or otherwise Controlled by iBio or any of its Affiliates and comprise iBio’s plant-based vaccine manufacturing platform.

 

		1.9	“iBio Additional Technology” will mean all Patents, Materials, Know-How, and
Trademarks (listed in Schedule C) owned (in whole or in part), in-licensed or otherwise Controlled by iBio or any of its Affiliates
at any time during the Term, which are not iBioLaunchTM Technology, and any Improvements thereto or any other research tools
or manufacturing techniques owned or otherwise Controlled by iBio or any of its Affiliates at any time during the Term and used
by iBio in the discovery, modification, or production of any proteins in plants for any purpose.

 

		1.10	“Improvement” will mean any development, invention, improvement, discovery,
modification, variation or revision to a compound, product or process within the iBioLaunchTM Technology or iBio Additional
Technology which is discovered, conceived or reduced to practice as a result of activities performed pursuant to this Agreement,
whether or not patentable, together with all intellectual property rights therein.

 

		1.11	“Improvement Patents” will mean all Patents which constitute an Improvement,
whether conceived or reduced to practice by iBio or Licensee, individually or jointly.

 

		1.12	“Know-How” will mean all commercial, technical, scientific and other know-how
and information, trade secrets, knowledge, technology, methods, processes, practices, formulae, instructions, skills, techniques,
procedures, experiences, ideas, technical assistance, designs, drawings, assembly procedures, computer programs, specifications,
data and results (including biological, chemical, pharmacological, toxicological, pharmaceutical, physical and analytical, preclinical,
clinical, safety, manufacturing and quality control data and know-how, including study designs and protocols), in all cases, whether
or not confidential, proprietary, patented or patentable, in written, electronic or any other form now known or hereafter developed.

 

		1.13	“Manufacture” and “Manufacturing” will mean all activities
related to the production, manufacture, processing, filling, finishing, packaging, labeling, shipping and holding of a Pharmaceutical
Product or any intermediate thereof, or of a Product or any intermediate thereof.

 

		1.14	“Materials” will mean any tangible chemical or biological material, including
any compounds, DNA, RNA, clones, launch vectors, cells, and any expression product, progeny, derivative or other Improvement thereto,
along with any tangible chemical or biological material embodying any Know-How.

 

     

     

    

 

		1.15	“Patent” will mean a patent or a patent application, including any additions,
divisions, continuations, continuations-in-part, invention certificates, substitutions, reissues, reexaminations, extensions, registrations,
supplementary protection certificates and renewals, but not including any rights that give rise to Regulatory Exclusivity Periods
(other than supplementary protection certificates, which will be treated as “Patents” hereunder) and including any
composition of matter, formulations, processes for making, dosing regimens, dosing devices, or uses of a pharmaceutical product.

 

		1.16	“Person” will mean any individual, corporation, partnership, limited liability
company, trust, governmental entity, or other legal entity of any nature whatsoever.

 

		1.17	“Pharmaceutical Products” will mean any product which is Covered by a Valid
Claim within the iBioLaunchTM Technology Patents and which is intended for use to prevent, vaccinate against, treat or cure
a disease or disorder in a human.

 

		1.18	“Product” will mean any product which is (a) Covered by a Patent within the
iBioLaunchTM Technology or the iBio Additional Technology, and (b) not a Pharmaceutical Product.

 

		1.19	“Process Development” will mean activities related to developing and scaling
up the ability to manufacture and to continue manufacturing Pharmaceutical Products or Products. Process Development includes,
but is not limited to, manufacturing process development and scale-up, quality assurance and quality control, and technical support.
Process Development does not include clinical studies, regulatory affairs activities and outside counsel regulatory legal services.

 

		1.20	“Prosecution and Maintenance” with regard to a particular Patent, will mean
the preparation, filing, prosecution and maintenance of such Patent, as well as re- examinations, reissues and the like with respect
to that Patent, together with the conduct of interferences, the defense of oppositions and other similar proceedings with respect
to that Patent.

 

		1.21	“R&D” means pre-clinical and early-stage clinical research and development
activities, including without limitation, feasibility assessments, formulation development, and activities useful or necessary
for seeking Regulatory Approval.

 

		1.22	“Regulatory Approval” will mean, with respect to a country or extra-national
territory, any and all approvals (including BLAs and MAAs), licenses, registrations or authorizations of any Regulatory Authority
necessary in order to commercially distribute, sell or market a product in such country or some or all of such extra-national territory,
but not including any pricing or reimbursement approvals.

 

		1.23	“Scale-Up” will mean the process of converting a laboratory-developed method
or procedure into a method, procedure, or protocol useful for manufacturing a commercial product, taking into account variables
such as, but not limited to, efficiency, yield, cost, safety, reproducibility, and stability.

 

     

     

    

 

		1.24	“Sublease” will mean that certain Sublease Agreement between College Station
Investors LLC, as Landlord, and iBio CMO LLC, as Tenant.

 

		1.25	“Sublicensee” will mean any person or entity (including Affiliates of Licensee)
that is granted a sublicense as permitted by Section 2.3 (or an option to take such a sublicense).

 

		1.26	“Technology Transfer” means the physical transfer from one Person to another
Person of a particular technology, including all information, documentation, skills, Know-How and other intellectual property rights
required to reproducibly operate such technology.

 

		1.27	“Territory” will mean the United States.

 

		1.28	“Third Party” will mean any person or entity other than iBio, Licensee and their
respective Affiliates.

 

		1.29	“Trademark” will mean trademarks, trade names, fictitious business names, service
marks, URLs, domain names, trade dress, logos, all common law rights to all marks, rights in all other indicia of source or origin,
and any associated goodwill.

 

		1.30	“United States” or “U.S.” will mean the United States of
America, including its territories, districts, commonwealths and possessions, including the District of Columbia and the Commonwealth
of Puerto Rico.

 

		1.31	“Valid Claim” will mean (a) an unexpired claim of an issued Patent which has
not been found to be unpatentable, invalid or unenforceable by a court, national or regional patent office, or other appropriate
body that has competent jurisdiction in the United States from which decision no appeal is taken or can be taken (except for writ
of certiorari); or (b) a pending claim of a pending Patent application which has not been pending for more than seven (7) years
since the date of its first substantive office action.

 

     

     

    

  

Schedule
B

 

iBioLaunchTM Patents

 

	Patent #	 	TITLE	 	Issue Date
	 	 	 	 	 
	“7,012,172”	 	VIRUS INDUCED GENE SILENCING IN PLANTS	 	3/14/2006
	 	 	 	 	 
	“7,491,509”	 	SYSTEM FOR EXPRESSION OF GENES IN PLANTS	 	2/17/2009
	 	 	 	 	 
	“7,683,238”	 	PRODUCTION OF PHARMACEUTICALLY ACTIVE PROTEINS IN SPROUTED SEEDLINGS	 	3/23/2010
	 	 	 	 	 
	“7,692,063”	 	PRODUCTION OF FOREIGN NUCLEIC ACIDS AND POLYPEPTIDES IN SPROUT SYSTEMS	 	4/6/2010
	 	 	 	 	 
	“8,058,511”	 	SYSTEM FOR EXPRESSION OF GENES IN PLANTS	 	11/15/2011
	 	 	 	 	 
	“8,148,608”	 	SYSTEMS AND METHODS FOR CLONAL EXPRESSION IN PLANTS	 	4/3/2012
	 	 	 	 	 
	“8,173,408”	 	“RECOMBINANT CARRIER MOLECULE FOR EXPRESSION, DELIVERY AND PURIFICATION OF TARGET POLYPEPTIDES”	 	5/8/2012
	 	 	 	 	 
	“8,591,909”	 	“RECOMBINANT CARRIER MOLECULE FOR EXPRESSION, DELIVERY AND PURIFICATION OF TARGET POLYPEPTIDES”	 	11/26/2013
	 	 	 	 	 
	“8,597,942”	 	SYSTEM FOR EXPRESSION OF GENES IN PLANTS	 	12/3/2013
	 	 	 	 	 
	“8,951,791”	 	SYSTEM FOR EXPRESSION OF GENES IN PLANTS	 	2/10/2015
	 	 	 	 	 
	“9,012,199”	 	“RECOMBINANT CARRIER MOLECULE FOR EXPRESSION, DELIVERY AND PURIFICATION OF TARGET POLYPEPTIDES”	 	4/21/2015

 

iBioLaunchTM Technology Trademarks

 

“iBioLaunch Technology”

 

     

     

    

  

Schedule C

 

iBio Additional Technology Trademarks

 

“iBioModulator Technology”

“iBio”

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00254-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00254-of-00352.parquet"}]]